

Michael R Hayden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/76154/publications.pdf>

Version: 2024-02-01

764
papers

72,901
citations

433

131
h-index

1216

227
g-index

793
all docs

793
docs citations

793
times ranked

41418
citing authors

#	ARTICLE	IF	CITATIONS
1	Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice. <i>Neurobiology of Disease</i> , 2022, 166, 105652.	2.1	12
2	Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease. <i>Journal of Neuroscience</i> , 2021, 41, 780-796.	1.7	37
3	Sigma-1 Receptor (S1R) Interaction with Cholesterol: Mechanisms of S1R Activation and Its Role in Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4082.	1.8	24
4	The Sigma-1 Receptor Mediates Pridopidine Rescue of Mitochondrial Function in Huntington Disease Models. <i>Neurotherapeutics</i> , 2021, 18, 1017-1038.	2.1	28
5	Pridopidine reduces mutant huntingtin-induced endoplasmic reticulum stress by modulation of the Sigma-1 receptor. <i>Journal of Neurochemistry</i> , 2021, 158, 467-481.	2.1	16
6	Super-resolution imaging reveals extrastriatal synaptic dysfunction in presymptomatic Huntington disease mice. <i>Neurobiology of Disease</i> , 2021, 152, 105293.	2.1	16
7	Reliable Resolution of Full-Length Huntingtin Alleles by Quantitative Immunoblotting. <i>Journal of Huntington's Disease</i> , 2021, 10, 355-365.	0.9	7
8	Orally bioavailable small molecule splicing modifiers with systemic and even htt-lowering activity in vitro and in vivo. , 2021, , .		0
9	Rescue of aberrant huntingtin palmitoylation ameliorates mutant huntingtin-induced toxicity. <i>Neurobiology of Disease</i> , 2021, 158, 105479.	2.1	16
10	Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1103-1115.	3.3	28
11	Neuroprotection of retinal ganglion cells by the sigma-1 receptor agonist pridopidine in models of experimental glaucoma. <i>Scientific Reports</i> , 2021, 11, 21975.	1.6	8
12	Quantification of Motor Function in Huntington Disease Patients Using Wearable Sensor Devices. <i>Digital Biomarkers</i> , 2020, 3, 103-115.	2.2	23
13	pS421 huntingtin modulates mitochondrial phenotypes and confers neuroprotection in an HD hiPSC model. <i>Cell Death and Disease</i> , 2020, 11, 809.	2.7	13
14	Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies. <i>Lancet Neurology</i> , The, 2020, 19, 930-939.	4.9	43
15	The Interaction of Aging and Cellular Stress Contributes to Pathogenesis in Mouse and Human Huntington Disease Neurons. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 524369.	1.7	21
16	Tracing the mutated HTT and haplotype of the African ancestor who spread Huntington disease into the Middle East. <i>Genetics in Medicine</i> , 2020, 22, 1903-1908.	1.1	8
17	Coupled Control of Distal Axon Integrity and Somal Responses to Axonal Damage by the Palmitoyl Acyltransferase ZDHHC17. <i>Cell Reports</i> , 2020, 33, 108365.	2.9	19
18	Frequency of the loss of CAA interruption in the HTT CAG tract and implications for Huntington disease in the reduced penetrance range. <i>Genetics in Medicine</i> , 2020, 22, 2108-2113.	1.1	32

#	ARTICLE	IF	CITATIONS
19	Gene expression profiles complement the analysis of genomic modifiers of the clinical onset of Huntington disease. <i>Human Molecular Genetics</i> , 2020, 29, 2788-2802.	1.4	17
20	DAPK1 Promotes Extrasynaptic GluN2B Phosphorylation and Striatal Spine Instability in the YAC128 Mouse Model of Huntington Disease. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 590569.	1.8	14
21	Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: Implications for the treatment of Huntington's disease. <i>Neurobiology of Disease</i> , 2020, 141, 104943.	2.1	11
22	Compromised IGF signaling causes caspase-6 activation in Huntington disease. <i>Experimental Neurology</i> , 2020, 332, 113396.	2.0	6
23	Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 402-410.	2.3	56
24	In search of a genetic explanation for LDLc variability in an FH family: common SNPs and a rare mutation in MTTP explain only part of LDL variability in an FH family. <i>Journal of Lipid Research</i> , 2019, 60, 1733-1740.	2.0	2
25	Activation of Caspase-6 Is Promoted by a Mutant Huntingtin Fragment and Blocked by an Allosteric Inhibitor Compound. <i>Cell Chemical Biology</i> , 2019, 26, 1295-1305.e6.	2.5	10
26	Impairment and Restoration of Homeostatic Plasticity in Cultured Cortical Neurons From a Mouse Model of Huntington Disease. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 209.	1.8	41
27	Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease. <i>American Journal of Human Genetics</i> , 2019, 104, 1116-1126.	2.6	130
28	Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor. <i>Neurobiology of Disease</i> , 2019, 129, 118-129.	2.1	48
29	Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9622-9627.	3.3	79
30	Altered Regulation of Striatal Neuronal N-Methyl-D-Aspartate Receptor Trafficking by Palmitoylation in Huntington Disease Mouse Model. <i>Frontiers in Synaptic Neuroscience</i> , 2019, 11, 3.	1.3	27
31	Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease. <i>Neurotherapeutics</i> , 2019, 16, 465-479.	2.1	47
32	A Comprehensive Haplotype-Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease. <i>American Journal of Human Genetics</i> , 2019, 105, 1112-1125.	2.6	23
33	Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease. <i>Nucleic Acids Research</i> , 2019, 48, 36-54.	6.5	41
34	Pridopidine, a clinically-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques. <i>Movement Disorders</i> , 2019, 34, 708-716.	2.2	32
35	Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. <i>Lancet Neurology</i> , The, 2019, 18, 165-176.	4.9	82
36	Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor. <i>Neurobiology of Disease</i> , 2019, 124, 489-504.	2.1	56

#	ARTICLE	IF	CITATIONS
37	Identification of a novel caspase cleavage site in huntingtin that regulates mutant huntingtin clearance. <i>FASEB Journal</i> , 2019, 33, 3190-3197.	0.2	20
38	Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease. <i>Molecular Neurobiology</i> , 2019, 56, 4464-4478.	1.9	27
39	The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2018, 177, 346-357.	1.1	60
40	Constitutive ablation of caspase-6 reduces the inflammatory response and behavioural changes caused by peripheral pro-inflammatory stimuli. <i>Cell Death Discovery</i> , 2018, 4, 40.	2.0	9
41	A whole brain longitudinal study in the YAC128 mouse model of Huntington's disease shows distinct trajectories of neurochemical, structural connectivity and volumetric changes. <i>Human Molecular Genetics</i> , 2018, 27, 2125-2137.	1.4	27
42	HACE1 is essential for astrocyte mitochondrial function and influences Huntington disease phenotypes in vivo. <i>Human Molecular Genetics</i> , 2018, 27, 239-253.	1.4	21
43	Further Investigation of the Role of <i>ACYP2</i> and <i>WFS1</i> Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 1866-1871.	3.2	32
44	Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease. <i>Acta Neuropathologica Communications</i> , 2018, 6, 16.	2.4	47
45	The global spectrum of protein-coding pharmacogenomic diversity. <i>Pharmacogenomics Journal</i> , 2018, 18, 187-195.	0.9	72
46	Genetic ablation of <i>Cyp8b1</i> preserves host metabolic function by repressing steatohepatitis and altering gut microbiota composition. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 314, E418-E432.	1.8	22
47	Characterization of subventricular zone-derived progenitor cells from mild and late symptomatic YAC128 mouse model of Huntington's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 34-44.	1.8	2
48	A43...Intrinsic mutant HTT-mediated defects in oligodendroglia cells contribute to myelin deficits and behavioural abnormalities in huntington disease. , 2018, , .		1
49	Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	89
50	Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse. <i>Molecular Neurodegeneration</i> , 2018, 13, 25.	4.4	26
51	Therapeutic approaches to Huntington disease: from the bench to the clinic. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 729-750.	21.5	117
52	A human huntingtin SNP alters post-translational modification and pathogenic proteolysis of the protein causing Huntington disease. <i>Scientific Reports</i> , 2018, 8, 8096.	1.6	38
53	Therapeutic modulation of the bile acid pool by <i>Cyp8b1</i> knockdown protects against nonalcoholic fatty liver disease in mice. <i>FASEB Journal</i> , 2018, 32, 3792-3802.	0.2	37
54	Altering cortical input unmask synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease. <i>BMC Biology</i> , 2018, 16, 58.	1.7	19

#	ARTICLE	IF	CITATIONS
55	IO9â€¦Antibodies inhibit cell to cell transmission of mutant HTT. , 2018, , .		0
56	Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research. <i>Progress in Neurobiology</i> , 2017, 152, 114-130.	2.8	29
57	Author response: Huntington disease reduced penetrance alleles occur at high frequency in the general population. <i>Neurology</i> , 2017, 88, 334-335.	1.5	0
58	Histone Deacetylase Inhibitors Protect Against Pyruvate Dehydrogenase Dysfunction in Huntington's Disease. <i>Journal of Neuroscience</i> , 2017, 37, 2776-2794.	1.7	50
59	Role of repeats in protein clearance. <i>Nature</i> , 2017, 545, 33-34.	13.7	4
60	Association Between <i>SLC16A5</i> Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer. <i>JAMA Oncology</i> , 2017, 3, 1558.	3.4	41
61	Palmitoylation of caspase-6 by HIP14 regulates its activation. <i>Cell Death and Differentiation</i> , 2017, 24, 433-444.	5.0	32
62	Pharmacogenomic screening for anthracyclineâ€¦induced cardiotoxicity in childhood cancer. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1143-1145.	1.1	13
63	The targetable A1 Huntington disease haplotype has distinct Amerindian and European origins in Latin America. <i>European Journal of Human Genetics</i> , 2017, 25, 332-340.	1.4	15
64	ABCA8 Regulates Cholesterol Efflux and High-Density Lipoprotein Cholesterol Levels. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 2147-2155.	1.1	55
65	A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles. <i>Human Molecular Genetics</i> , 2017, 26, ddx021.	1.4	37
66	A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis. <i>Genome Medicine</i> , 2017, 9, 50.	3.6	25
67	eEF2K inhibition blocks A ²⁴² neurotoxicity by promoting an NRF2 antioxidant response. <i>Acta Neuropathologica</i> , 2017, 133, 101-119.	3.9	48
68	The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. <i>Neurobiology of Disease</i> , 2017, 97, 46-59.	2.1	105
69	Comparative Mitochondrial-Based Protective Effects of Resveratrol and Nicotinamide in Huntingtonâ€™s Disease Models. <i>Molecular Neurobiology</i> , 2017, 54, 5385-5399.	1.9	105
70	Epidemiology of Huntington disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2017, 144, 31-46.	1.0	43
71	Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation <i>in vivo</i> in a mouse model. <i>Annals of the New York Academy of Sciences</i> , 2017, 1407, 75-89.	1.8	7
72	Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. <i>JCI Insight</i> , 2017, 2, .	2.3	39

#	ARTICLE	IF	CITATIONS
73	A true mentor and pioneer in medical genetics. <i>South African Medical Journal</i> , 2016, 106, 7.	0.2	0
74	Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 28-39.	0.7	21
75	A novel microdeletion affecting the <i>CETP</i> gene raises HDL-associated cholesterol levels. <i>Clinical Genetics</i> , 2016, 89, 495-500.	1.0	0
76	Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons. <i>Experimental Neurology</i> , 2016, 283, 121-128.	2.0	26
77	B42...Early olfactory behaviour deficits associated with olfactory bulb atrophy and caspase-8 activation in HD rodent models. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A24.1-A24.	0.9	0
78	Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study. <i>Brain</i> , 2016, 139, 2050-2062.	3.7	53
79	Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition. <i>Journal of Neuroimmunology</i> , 2016, 290, 84-95.	1.1	21
80	Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin. <i>Neuroscience</i> , 2016, 325, 74-88.	1.1	34
81	Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6145-E6152.	3.3	111
82	Pridopidine activates neuroprotective pathways impaired in Huntington Disease. <i>Human Molecular Genetics</i> , 2016, 25, 3975-3987.	1.4	65
83	Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 683-695.	1.1	188
84	Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells. <i>Journal of Neurochemistry</i> , 2016, 137, 782-794.	2.1	30
85	An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes. <i>Human Molecular Genetics</i> , 2016, 25, 3654-3675.	1.4	85
86	Huntington disease reduced penetrance alleles occur at high frequency in the general population. <i>Neurology</i> , 2016, 87, 282-288.	1.5	82
87	Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. <i>Scientific Reports</i> , 2016, 6, 31652.	1.6	59
88	Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes. <i>Scientific Reports</i> , 2016, 6, 25333.	1.6	130
89	Sudden death due to paralysis and synaptic and behavioral deficits when <i>Hip14/Zdhc17</i> is deleted in adult mice. <i>BMC Biology</i> , 2016, 14, 108.	1.7	22
90	Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease. <i>Human Molecular Genetics</i> , 2016, 25, ddw122.	1.4	62

#	ARTICLE	IF	CITATIONS
91	ABCA1 deficiency and cellular cholesterol accumulation increases islet amyloidogenesis in mice. <i>Diabetologia</i> , 2016, 59, 1242-1246.	2.9	24
92	Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease. <i>Experimental Neurology</i> , 2016, 278, 4-10.	2.0	38
93	Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease. <i>Molecular Therapy - Nucleic Acids</i> , 2016, 5, e297.	2.3	97
94	Interactome network analysis identifies multiple caspase-6 interactors involved in the pathogenesis of HD. <i>Human Molecular Genetics</i> , 2016, 25, 1600-1618.	1.4	14
95	Insulin and IGF-1 regularize energy metabolites in neural cells expressing full-length mutant huntingtin. <i>Neuropeptides</i> , 2016, 58, 73-81.	0.9	28
96	Aberrant palmitoylation in Huntington disease. <i>Biochemical Society Transactions</i> , 2015, 43, 205-210.	1.6	27
97	696. Pre-Clinical Evaluation of Allele-Specific Mutant Huntingtin Gene Silencing Antisense Oligonucleotides. <i>Molecular Therapy</i> , 2015, 23, S277.	3.7	0
98	Curation of the Mammalian Palmitoylome Indicates a Pivotal Role for Palmitoylation in Diseases and Disorders of the Nervous System and Cancers. <i>PLoS Computational Biology</i> , 2015, 11, e1004405.	1.5	120
99	Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids. <i>Scientific Reports</i> , 2015, 5, 10191.	1.6	14
100	A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers. <i>Movement Disorders</i> , 2015, 30, 393-401.	2.2	50
101	Direct intracerebral delivery of a miR-33 antisense oligonucleotide into mouse brain increases brain ABCA1 expression. <i>Neuroscience Letters</i> , 2015, 598, 66-72.	1.0	26
102	Loss of <i>Cyp8b1</i> Improves Glucose Homeostasis by Increasing GLP-1. <i>Diabetes</i> , 2015, 64, 1168-1179.	0.3	89
103	Huntingtin interacting proteins 14 and 14-like are required for chorioallantoic fusion during early placental development. <i>Developmental Biology</i> , 2015, 397, 257-266.	0.9	8
104	Partial rescue of some features of Huntington Disease in the genetic absence of caspase-6 in YAC128 mice. <i>Neurobiology of Disease</i> , 2015, 76, 24-36.	2.1	48
105	Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. <i>Neurobiology of Disease</i> , 2015, 76, 46-56.	2.1	78
106	Biophysical and Biological Characterization of Hairpin and Molecular Beacon RNase H Active Antisense Oligonucleotides. <i>ACS Chemical Biology</i> , 2015, 10, 1227-1233.	1.6	12
107	Human genetics of HDL: Insight into particle metabolism and function. <i>Progress in Lipid Research</i> , 2015, 58, 14-25.	5.3	45
108	A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits. <i>Human Molecular Genetics</i> , 2015, 24, 2604-2614.	1.4	48

#	ARTICLE	IF	CITATIONS
109	Genetic variants in <i>SLC22A17</i> and <i>SLC22A7</i> are associated with anthracycline-induced cardiotoxicity in children. <i>Pharmacogenomics</i> , 2015, 16, 1065-1076.	0.6	95
110	A coding variant in <i>RARG</i> confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. <i>Nature Genetics</i> , 2015, 47, 1079-1084.	9.4	214
111	Systematic interaction network filtering identifies <i>CRMP1</i> as a novel suppressor of huntingtin misfolding and neurotoxicity. <i>Genome Research</i> , 2015, 25, 701-713.	2.4	24
112	A SNP in the <i>HTT</i> promoter alters NF- κ B binding and is a bidirectional genetic modifier of Huntington disease. <i>Nature Neuroscience</i> , 2015, 18, 807-816.	7.1	113
113	Clinical Exome/Genome Reports-Announcement. <i>Clinical Genetics</i> , 2015, 87, 99-99.	1.0	0
114	Huntington disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15005.	18.1	1,031
115	HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. <i>Human Molecular Genetics</i> , 2015, 24, 3257-3271.	1.4	102
116	Post-translational myristoylation at the cross roads of cell death, autophagy and neurodegeneration. <i>Biochemical Society Transactions</i> , 2015, 43, 229-234.	1.6	20
117	Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry. <i>Molecular Therapy</i> , 2015, 23, 1759-1771.	3.7	73
118	Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. <i>Scientific Reports</i> , 2015, 5, 12166.	1.6	82
119	Targeted next-generation sequencing to diagnose disorders of HDL cholesterol. <i>Journal of Lipid Research</i> , 2015, 56, 1993-2001.	2.0	28
120	Comment on Rickels et al. Loss-of-Function Mutations in <i>ABCA1</i> and Enhanced β -Cell Secretory Capacity in Young Adults. <i>Diabetes</i> 2015;64:193-199. <i>Diabetes</i> , 2015, 64, e25-e26.	0.3	2
121	A new mutation for Huntington disease following maternal transmission of an intermediate allele. <i>European Journal of Medical Genetics</i> , 2015, 58, 28-30.	0.7	22
122	Inhibition of Excessive Monoamine Oxidase A/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease. <i>Molecular Neurobiology</i> , 2015, 52, 1850-1861.	1.9	31
123	Autophagy in Huntington disease and huntingtin in autophagy. <i>Trends in Neurosciences</i> , 2015, 38, 26-35.	4.2	277
124	Clinical, Biochemical, and Molecular Characterization of Novel Mutations in <i>ABCA1</i> in Families with Tangier Disease. <i>JIMD Reports</i> , 2014, 18, 51-62.	0.7	19
125	p53 increases caspase-6 expression and activation in muscle tissue expressing mutant huntingtin. <i>Human Molecular Genetics</i> , 2014, 23, 717-729.	1.4	42
126	<i>HACE1</i> reduces oxidative stress and mutant Huntington toxicity by promoting the NRF2 response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 3032-3037.	3.3	85

#	ARTICLE	IF	CITATIONS
127	Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent. <i>Pharmacogenomics Journal</i> , 2014, 14, 160-170.	0.9	29
128	Identification of a post-translationally myristoylated autophagy-inducing domain released by caspase cleavage of Huntingtin. <i>Human Molecular Genetics</i> , 2014, 23, 3166-3179.	1.4	56
129	Hepatic ABCA1 Expression Improves β -Cell Function and Glucose Tolerance. <i>Diabetes</i> , 2014, 63, 4076-4082.	0.3	19
130	Two novel mutations in apolipoprotein C3 underlie atheroprotective lipid profiles in families. <i>Clinical Genetics</i> , 2014, 85, 433-440.	1.0	19
131	In Vivo Evaluation of Candidate Allele-specific Mutant Huntingtin Gene Silencing Antisense Oligonucleotides. <i>Molecular Therapy</i> , 2014, 22, 2093-2106.	3.7	115
132	Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 253-253.	2.3	20
133	The emerging era of pharmacogenomics: current successes, future potential, and challenges. <i>Clinical Genetics</i> , 2014, 86, 21-28.	1.0	68
134	Development of a broad-based ADME panel for use in pharmacogenomic studies. <i>Pharmacogenomics</i> , 2014, 15, 1185-1195.	0.6	8
135	Bidirectional Control of Postsynaptic Density-95 (PSD-95) Clustering by Huntingtin. <i>Journal of Biological Chemistry</i> , 2014, 289, 3518-3528.	1.6	30
136	The palmitoyl acyltransferase HIP14 shares a high proportion of interactors with huntingtin: implications for a role in the pathogenesis of Huntington's disease. <i>Human Molecular Genetics</i> , 2014, 23, 4142-4160.	1.4	58
137	IGF-1 Intranasal Administration Rescues Huntington's Disease Phenotypes in YAC128 Mice. <i>Molecular Neurobiology</i> , 2014, 49, 1126-1142.	1.9	60
138	Evidence-based genetic counselling implications for Huntington disease intermediate allele predictive test results. <i>Clinical Genetics</i> , 2014, 85, 303-311.	1.0	35
139	Personalized gene silencing therapeutics for Huntington disease. <i>Clinical Genetics</i> , 2014, 86, 29-36.	1.0	44
140	Codeine-related deaths: The role of pharmacogenetics and drug interactions. <i>Forensic Science International</i> , 2014, 239, 50-56.	1.3	41
141	Developmental Biology: Frontiers for Clinical Genetics. <i>Clinical Genetics</i> , 2014, 86, no.	1.0	2
142	High density lipoprotein metabolism in low density lipoprotein receptor-deficient mice. <i>Journal of Lipid Research</i> , 2014, 55, 1914-1924.	2.0	17
143	Pharmacogenomic diversity in Singaporean populations and Europeans. <i>Pharmacogenomics Journal</i> , 2014, 14, 555-563.	0.9	15
144	Identification of four novel genes contributing to familial elevated plasma HDL cholesterol in humans. <i>Journal of Lipid Research</i> , 2014, 55, 1693-1701.	2.0	24

#	ARTICLE	IF	CITATIONS
145	ABCA1 in adipocytes regulates adipose tissue lipid content, glucose tolerance, and insulin sensitivity. <i>Journal of Lipid Research</i> , 2014, 55, 516-523.	2.0	76
146	Use of genetic technologies to compare medicines. <i>Clinical Genetics</i> , 2014, 86, 441-446.	1.0	0
147	Public Perceptions of Pharmacogenetics. <i>Pediatrics</i> , 2014, 133, e1258-e1267.	1.0	26
148	Response to "Evaluation of Pharmacogenetic Markers to Predict the Risk of Cisplatin-Induced Ototoxicity". <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 158-158.	2.3	2
149	Laquinimod exerts strong clinical and immunomodulatory effects in Lewis rat experimental autoimmune neuritis. <i>Journal of Neuroimmunology</i> , 2014, 274, 38-45.	1.1	15
150	Genetic Markers of Cisplatin-Induced Hearing Loss in Children. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 296-298.	2.3	7
151	<i>VKORC1</i> and <i>CYP2C9</i> genotypes are predictors of warfarin-related outcomes in children. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1055-1062.	0.8	36
152	Multisource ascertainment of Huntington disease in Canada: Prevalence and population at risk. <i>Movement Disorders</i> , 2014, 29, 105-114.	2.2	125
153	Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic. <i>PLoS ONE</i> , 2014, 9, e83757.	1.1	35
154	Identification of Binding Sites in Huntingtin for the Huntingtin Interacting Proteins HIP14 and HIP14L. <i>PLoS ONE</i> , 2014, 9, e90669.	1.1	24
155	Striatal Synaptic Dysfunction and Hippocampal Plasticity Deficits in the Hu97/18 Mouse Model of Huntington Disease. <i>PLoS ONE</i> , 2014, 9, e94562.	1.1	35
156	Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients. <i>PLoS ONE</i> , 2014, 9, e107434.	1.1	92
157	Abstract W P205: Specific Deficiency of Brain ABCA1 Increases Inflammation and White Matter Damage and Worsens Functional Outcome After Stroke. <i>Stroke</i> , 2014, 45, .	1.0	0
158	"Grasping the Grey": Patient Understanding and Interpretation of an Intermediate Allele Predictive Test Result for Huntington Disease. <i>Journal of Genetic Counseling</i> , 2013, 22, 200-217.	0.9	25
159	Replication of TPMT and ABCC3 Genetic Variants Highly Associated With Cisplatin-Induced Hearing Loss in Children. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 243-251.	2.3	109
160	Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models. <i>Nature Medicine</i> , 2013, 19, 1030-1038.	15.2	108
161	Hunting human disease genes: lessons from the past, challenges for the future. <i>Human Genetics</i> , 2013, 132, 603-617.	1.8	31
162	HLA-A*31:01 and HLA-B*15:02 as Genetic Markers for Carbamazepine Hypersensitivity in Children. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 142-149.	2.3	110

#	ARTICLE	IF	CITATIONS
163	Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes. <i>European Journal of Human Genetics</i> , 2013, 21, 1120-1127.	1.4	52
164	CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease. <i>Journal of Medical Genetics</i> , 2013, 50, 696-703.	1.5	65
165	A systematic review and meta-analysis of clinical variables used in Huntington disease research. <i>Movement Disorders</i> , 2013, 28, 1987-1994.	2.2	8
166	Choosing an animal model for the study of Huntington's disease. <i>Nature Reviews Neuroscience</i> , 2013, 14, 708-721.	4.9	287
167	Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset. <i>Neurogenetics</i> , 2013, 14, 173-179.	0.7	10
168	High frequency of intermediate alleles on huntington disease-associated haplotypes in British Columbia's general population. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2013, 162, 864-871.	1.1	44
169	Special new feature in <i>Clinical Genetics</i> . <i>Clinical Genetics</i> , 2013, 83, 1-1.	1.0	0
170	Hip14l-deficient mice develop neuropathological and behavioural features of Huntington disease. <i>Human Molecular Genetics</i> , 2013, 22, 452-465.	1.4	59
171	Tracking Brain Palmitoylation Change: Predominance of Glial Change in a Mouse Model of Huntington's Disease. <i>Chemistry and Biology</i> , 2013, 20, 1421-1434.	6.2	81
172	ABCA1 influences neuroinflammation and neuronal death. <i>Neurobiology of Disease</i> , 2013, 54, 445-455.	2.1	71
173	Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. <i>Nucleic Acids Research</i> , 2013, 41, 9634-9650.	6.5	138
174	Cancer Pharmacogenomics in Children: Research Initiatives and Progress to Date. <i>Paediatric Drugs</i> , 2013, 15, 71-81.	1.3	8
175	From Mutation Identification to Therapy: Discovery and Origins of the First Approved Gene Therapy in the Western World. <i>Human Gene Therapy</i> , 2013, 24, 472-478.	1.4	41
176	A fully humanized transgenic mouse model of Huntington disease. <i>Human Molecular Genetics</i> , 2013, 22, 18-34.	1.4	93
177	Developing a comprehensive, effective patient-friendly website to enhance decision making in predictive testing for Huntington disease. <i>Genetics in Medicine</i> , 2013, 15, 466-472.	1.1	8
178	When access is an issue: exploring barriers to predictive testing for Huntington disease in British Columbia, Canada. <i>European Journal of Human Genetics</i> , 2013, 21, 148-153.	1.4	20
179	Intrinsic cleavage of receptor-interacting protein kinase-1 by caspase-6. <i>Cell Death and Differentiation</i> , 2013, 20, 86-96.	5.0	36
180	The Salmonella Type III Effector SspH2 Specifically Exploits the NLR Co-chaperone Activity of SGT1 to Subvert Immunity. <i>PLoS Pathogens</i> , 2013, 9, e1003518.	2.1	80

#	ARTICLE	IF	CITATIONS
181	The Impact of Partial and Complete Loss-of-Function Mutations in Endothelial Lipase on High-Density Lipoprotein Levels and Functionality in Humans. <i>Circulation: Cardiovascular Genetics</i> , 2013, 6, 54-62.	5.1	53
182	Regulation of ABCA1 Protein Expression and Function in Hepatic and Pancreatic Islet Cells by miR-145. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 2724-2732.	1.1	106
183	Putative Association of ABCB1 2677G>T/A With Oxycodone-Induced Central Nervous System Depression in Breastfeeding Mothers. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 466-472.	1.0	17
184	De novo Huntington disease caused by 26-44 CAG repeat expansion on a low-risk haplotype. <i>Neurology</i> , 2013, 81, 1099-1100.	1.5	11
185	Memory and synaptic deficits in <i>Hip14/DHHC17</i> knockout mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 20296-20301.	3.3	45
186	Providing predictive testing for Huntington disease via telehealth: results of a pilot study in British Columbia, Canada. <i>Clinical Genetics</i> , 2013, 84, 60-64.	1.0	29
187	Validation of variants in <i>SLC28A3</i> and <i>UGT1A6</i> as genetic markers predictive of anthracycline-induced cardiotoxicity in children. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1375-1381.	0.8	166
188	Antisense Oligonucleotide-Mediated Correction of Transcriptional Dysregulation is Correlated with Behavioral Benefits in the YAC128 Mouse Model of Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2013, 2, 217-228.	0.9	58
189	Life-Threatening Adverse Events Following Therapeutic Opioid Administration in Adults: Is Pharmacogenetic Analysis Useful?. <i>Pain Research and Management</i> , 2013, 18, 133-136.	0.7	17
190	A Clinical Tool for Reducing Central Nervous System Depression among Neonates Exposed to Codeine through Breast Milk. <i>PLoS ONE</i> , 2013, 8, e70073.	1.1	34
191	Pharmacogenomics of vincristine-induced neurotoxicity in pediatric cancer patients. <i>FASEB Journal</i> , 2013, 27, 666.3.	0.2	0
192	An investigation of morphine-to-codeine metabolic ratios in postmortem blood, drug interactions, and cytochrome P450 2D6 (CYP2D6) genotype. <i>FASEB Journal</i> , 2013, 27, 666.2.	0.2	0
193	Predicting Anthracycline-Induced Cardiotoxicity in Children - Genome-Wide Association Study. <i>FASEB Journal</i> , 2013, 27, 663.3.	0.2	0
194	Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. <i>Human Molecular Genetics</i> , 2012, 21, 2219-2232.	1.4	122
195	Postpartum Maternal Codeine Therapy and the Risk of Adverse Neonatal Outcomes. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 378-380.	1.0	11
196	Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice. <i>Human Molecular Genetics</i> , 2012, 21, 1954-1967.	1.4	67
197	Peripheral and cerebral metabolic features in an animal model of Huntington's disease. , 2012, , .		1
198	miR-33a Modulates ABCA1 Expression, Cholesterol Accumulation, and Insulin Secretion in Pancreatic Islets. <i>Diabetes</i> , 2012, 61, 653-658.	0.3	122

#	ARTICLE	IF	CITATIONS
199	Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children. <i>Journal of Clinical Oncology</i> , 2012, 30, 1422-1428.	0.8	341
200	Transgenic Mouse Model Expressing the Caspase 6 Fragment of Mutant Huntingtin. <i>Journal of Neuroscience</i> , 2012, 32, 183-193.	1.7	49
201	Caspase-6-Resistant Mutant Huntingtin Does not Rescue the Toxic Effects of Caspase-Cleavable Mutant Huntingtin in vivo. <i>Journal of Huntington's Disease</i> , 2012, 1, 243-260.	0.9	7
202	Personalized Medicine: Temper Expectationsâ€™Response. <i>Science</i> , 2012, 337, 911-911.	6.0	2
203	Prediction of Codeine Toxicity in Infants and Their Mothers Using a Novel Combination of Maternal Genetic Markers. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 692-699.	2.3	69
204	Human Mendelian pain disorders: a key to discovery and validation of novel analgesics. <i>Clinical Genetics</i> , 2012, 82, 367-373.	1.0	34
205	CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. <i>Neurology</i> , 2012, 78, 690-695.	1.5	303
206	Polyglutamine diseases and the risk of cancer. <i>Lancet Oncology</i> , The, 2012, 13, 569-571.	5.1	1
207	Population stratification may bias analysis of PGC-1 β as a modifier of age at Huntington disease motor onset. <i>Human Genetics</i> , 2012, 131, 1833-1840.	1.8	26
208	Putting proteins in their place: Palmitoylation in Huntington disease and other neuropsychiatric diseases. <i>Progress in Neurobiology</i> , 2012, 97, 220-238.	2.8	118
209	Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2012, 1821, 416-424.	1.2	50
210	TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntingtonâ€™s disease. <i>Biochemical and Biophysical Research Communications</i> , 2012, 424, 404-408.	1.0	20
211	More Codeine Fatalities After Tonsillectomy in North American Children. <i>Pediatrics</i> , 2012, 129, e1343-e1347.	1.0	334
212	Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. <i>Trends in Molecular Medicine</i> , 2012, 18, 634-643.	3.5	116
213	NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease. <i>Neurobiology of Disease</i> , 2012, 48, 282-289.	2.1	47
214	Apnea and Oxygen Desaturations in Children Treated with Opioids after Adenotonsillectomy for Obstructive Sleep Apnea Syndrome. <i>Paediatric Drugs</i> , 2012, 14, 411-415.	1.3	29
215	Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. <i>Pharmacogenomics Journal</i> , 2012, 12, 233-237.	0.9	158
216	Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background. <i>Journal of Huntington's Disease</i> , 2012, 1, 221-241.	0.9	13

#	ARTICLE	IF	CITATIONS
217	Economic impact of a genetic test for cisplatin-induced ototoxicity. <i>Pharmacogenomics Journal</i> , 2012, 12, 205-213.	0.9	21
218	Loss of Both ABCA1 and ABCG1 Results in Increased Disturbances in Islet Sterol Homeostasis, Inflammation, and Impaired β -Cell Function. <i>Diabetes</i> , 2012, 61, 659-664.	0.3	107
219	Whole-Genome Sequencing: The New Standard of Care?. <i>Science</i> , 2012, 336, 1112-1113.	6.0	63
220	Common SNP-Based Haplotype Analysis of the 4p16.3 Huntington Disease Gene Region. <i>American Journal of Human Genetics</i> , 2012, 90, 434-444.	2.6	60
221	Adoption and the communication of genetic risk: experiences in Huntington disease. <i>Clinical Genetics</i> , 2012, 81, 64-69.	1.0	7
222	What monozygotic twins discordant for phenotype illustrate about mechanisms influencing genetic forms of neurodegeneration. <i>Clinical Genetics</i> , 2012, 81, 325-333.	1.0	36
223	Central Nervous System Depression of Neonates Breastfed by Mothers Receiving Oxycodone for Postpartum Analgesia. <i>Journal of Pediatrics</i> , 2012, 160, 33-37.e2.	0.9	108
224	Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. <i>Neurobiology of Disease</i> , 2012, 45, 438-449.	2.1	105
225	Treatment of Nav1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. <i>Pain</i> , 2012, 153, 80-85.	2.0	116
226	Beyond the patient: The broader impact of genetic discrimination among individuals at risk of Huntington disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2012, 159B, 217-226.	1.1	37
227	Low Levels of Human HIP14 Are Sufficient to Rescue Neuropathological, Behavioural, and Enzymatic Defects Due to Loss of Murine HIP14 in <i>Hip14^{-/-}</i> Mice. <i>PLoS ONE</i> , 2012, 7, e36315.	1.1	10
228	Segregation of LIPC, CETP, and GALNT2 Mutations in Caucasian Families with Extremely High HDL Cholesterol. <i>PLoS ONE</i> , 2012, 7, e37437.	1.1	28
229	Apnea and Oxygen Desaturations in Children Treated with Opioids after Adenotonsillectomy for Obstructive Sleep Apnea Syndrome. <i>Paediatric Drugs</i> , 2012, 14, 411-415.	1.3	12
230	Diagnostic Testing for Vaccinomics: Is the Regulatory Approval Framework Adequate? A Comparison of Canada, the United States, and Europe. <i>OMICS A Journal of Integrative Biology</i> , 2011, 15, 597-605.	1.0	3
231	Small Changes, Big Impact. <i>Neuroscientist</i> , 2011, 17, 475-492.	2.6	159
232	Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 853-867.	21.5	70
233	Altered palmitoylation and neuropathological deficits in mice lacking HIP14. <i>Human Molecular Genetics</i> , 2011, 20, 3899-3909.	1.4	103
234	The Dynamics of Macrophage Infiltration into the Arterial Wall during Atherosclerotic Lesion Development in Low-Density Lipoprotein Receptor Knockout Mice. <i>American Journal of Pathology</i> , 2011, 178, 413-422.	1.9	24

#	ARTICLE	IF	CITATIONS
235	Islet Cholesterol Accumulation Due to Loss of ABCA1 Leads to Impaired Exocytosis of Insulin Granules. <i>Diabetes</i> , 2011, 60, 3186-3196.	0.3	97
236	Caspase-6 and neurodegeneration. <i>Trends in Neurosciences</i> , 2011, 34, 646-656.	4.2	114
237	Lessons from predictive testing for Huntington disease: 25 years on. <i>Journal of Medical Genetics</i> , 2011, 48, 649-650.	1.5	17
238	Potent and Selective Antisense Oligonucleotides Targeting Single-Nucleotide Polymorphisms in the Huntington Disease Gene / Allele-Specific Silencing of Mutant Huntingtin. <i>Molecular Therapy</i> , 2011, 19, 2178-2185.	3.7	246
239	Cholesterol metabolism in Huntington disease. <i>Nature Reviews Neurology</i> , 2011, 7, 561-572.	4.9	122
240	Amelioration of Hypertriglyceridemia with Hypo-Alpha-Cholesterolemia in LPL Deficient Mice by Hematopoietic Cell-Derived LPL. <i>PLoS ONE</i> , 2011, 6, e25620.	1.1	4
241	CYP2D6 Polymorphisms and Codeine Analgesia in Postpartum Pain Management: A Pilot Study. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 425-432.	1.0	45
242	Pharmacogenomics of Cardiovascular Drugs and Adverse Effects in Pediatrics. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 58, 228-239.	0.8	22
243	Novel mutations in scavenger receptor BI associated with high HDL cholesterol in humans. <i>Clinical Genetics</i> , 2011, 79, 575-581.	1.0	70
244	Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. <i>Nature Medicine</i> , 2011, 17, 377-382.	15.2	467
245	HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. <i>European Journal of Human Genetics</i> , 2011, 19, 561-566.	1.4	140
246	Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of Huntington disease. <i>Neurobiology of Disease</i> , 2011, 41, 249-260.	2.1	92
247	Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease. <i>Neurobiology of Disease</i> , 2011, 43, 257-265.	2.1	65
248	Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease. <i>Molecular Neurodegeneration</i> , 2011, 6, 59.	4.4	30
249	Factors associated with experiences of genetic discrimination among individuals at risk for huntington disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2011, 156, 19-27.	1.1	14
250	A grand challenge: Providing benefits of clinical genetics to those in need. <i>Genetics in Medicine</i> , 2011, 13, 197-200.	1.1	54
251	Wild-type HTT modulates the enzymatic activity of the neuronal palmitoyl transferase HIP14. <i>Human Molecular Genetics</i> , 2011, 20, 3356-3365.	1.4	71
252	A Quantitative Method for the Specific Assessment of Caspase-6 Activity in Cell Culture. <i>PLoS ONE</i> , 2011, 6, e27680.	1.1	27

#	ARTICLE	IF	CITATIONS
253	Unstable familial transmissions of Huntington disease alleles with 27-35 CAG repeats (intermediate) Tj ETQq1 1 0,784314,rgBT /Over	1.1	37
254	HDL and LDL cholesterol significantly influence β -cell function in type 2 diabetes mellitus. <i>Current Opinion in Lipidology</i> , 2010, 21, 178-185.	1.2	120
255	Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. <i>Diabetologia</i> , 2010, 53, 1110-1119.	2.9	108
256	Cholesterol toxicity in pancreatic islets from LDL receptor-deficient mice. Reply to: de Souza JC, de Oliveira CAM, Carneiro EM et al. [letter]. <i>Diabetologia</i> , 2010, 53, 2463-2464.	2.9	1
257	Cholesterol in β -cell Dysfunction: The Emerging Connection Between HDL Cholesterol and Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2010, 10, 55-60.	1.7	54
258	Palmitoylation and function of glial glutamate transporter-1 is reduced in the YAC128 mouse model of Huntington disease. <i>Neurobiology of Disease</i> , 2010, 40, 207-215.	2.1	90
259	Adenosine-Triphosphate-Binding Cassette Transporter-1 Trafficking and Function. <i>Trends in Cardiovascular Medicine</i> , 2010, 20, 41-49.	2.3	37
260	CAG repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 397-408.	1.1	289
261	Perception, experience, and response to genetic discrimination in Huntington disease: The international RESPOND ^{HD} study. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 1081-1093.	1.1	42
262	In their own words: Reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND ^{HD} study. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 1150-1159.	1.1	33
263	Communicating Pharmacogenetic Research Results to Breastfeeding Mothers Taking Codeine: A Pilot Study of Perceptions and Benefits. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 792-795.	2.3	23
264	BDNF Overexpression in the Forebrain Rescues Huntington's Disease Phenotypes in YAC128 Mice. <i>Journal of Neuroscience</i> , 2010, 30, 14708-14718.	1.7	223
265	Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis. <i>Human Molecular Genetics</i> , 2010, 19, 1438-1452.	1.4	91
266	Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. <i>Human Molecular Genetics</i> , 2010, 19, 1528-1538.	1.4	100
267	Glucose intolerance and decreased early insulin response in mice with severe hypertriglyceridemia. <i>Experimental Biology and Medicine</i> , 2010, 235, 40-46.	1.1	9
268	Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia. <i>Journal of Lipid Research</i> , 2010, 51, 1535-1545.	2.0	103
269	Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. <i>Neurology</i> , 2010, 75, 1702-1710.	1.5	107
270	Targeted Deletion of Hepatocyte ABCA1 Leads to Very Low Density Lipoprotein Triglyceride Overproduction and Low Density Lipoprotein Hypercatabolism. <i>Journal of Biological Chemistry</i> , 2010, 285, 12197-12209.	1.6	81

#	ARTICLE	IF	CITATIONS
271	The Canadian Pharmacogenomics Network for Drug Safety: A Model for Safety Pharmacology. <i>Thyroid</i> , 2010, 20, 681-687.	2.4	67
272	Fatal Hydrocodone Overdose in a Child: Pharmacogenetics and Drug Interactions. <i>Pediatrics</i> , 2010, 126, e986-e989.	1.0	84
273	A functional ABCA1 gene variant is associated with low HDL-cholesterol levels and shows evidence of positive selection in Native Americans. <i>Human Molecular Genetics</i> , 2010, 19, 2877-2885.	1.4	133
274	Phosphorylation of Huntingtin at Ser ⁴²¹ in YAC128 Neurons Is Associated with Protection of YAC128 Neurons from NMDA-Mediated Excitotoxicity and Is Modulated by PP1 and PP2A. <i>Journal of Neuroscience</i> , 2010, 30, 14318-14329.	1.7	81
275	Cleavage at the 586 Amino Acid Caspase-6 Site in Mutant huntingtin Influences Caspase-6 Activation <i>In Vivo</i> . <i>Journal of Neuroscience</i> , 2010, 30, 15019-15029.	1.7	94
276	Carriers of Loss-of-Function Mutations in ABCA1 Display Pancreatic β -Cell Dysfunction. <i>Diabetes Care</i> , 2010, 33, 869-874.	4.3	114
277	Cholesterol Defect Is Marked across Multiple Rodent Models of Huntington's Disease and Is Manifest in Astrocytes. <i>Journal of Neuroscience</i> , 2010, 30, 10844-10850.	1.7	136
278	Pharmacogenomics and active surveillance for serious adverse drug reactions in children. <i>Pharmacogenomics</i> , 2010, 11, 1269-1285.	0.6	19
279	Cocaine adulterant linked to neutropenia. <i>Cmaj</i> , 2010, 182, 57-59.	0.9	25
280	The metabolic phenotype of SCD1-deficient mice is independent of melanin-concentrating hormone. <i>Peptides</i> , 2010, 31, 123-129.	1.2	2
281	Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice. <i>Neuron</i> , 2010, 65, 178-190.	3.8	448
282	Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice. <i>Neuron</i> , 2010, 65, 436.	3.8	2
283	Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis. <i>Atherosclerosis</i> , 2010, 211, 231-236.	0.4	64
284	Interaction of Postsynaptic Density Protein-95 with NMDA Receptors Influences Excitotoxicity in the Yeast Artificial Chromosome Mouse Model of Huntington's Disease. <i>Journal of Neuroscience</i> , 2009, 29, 10928-10938.	1.7	85
285	Tissue-Specific Roles of ABCA1 Influence Susceptibility to Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 548-554.	1.1	98
286	Palmitoylation of ATP-Binding Cassette Transporter A1 Is Essential for Its Trafficking and Function. <i>Circulation Research</i> , 2009, 105, 138-147.	2.0	70
287	Despite Antiatherogenic Metabolic Characteristics, SCD1-Deficient Mice Have Increased Inflammation and Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 341-347.	1.1	95
288	Specific Loss of Brain ABCA1 Increases Brain Cholesterol Uptake and Influences Neuronal Structure and Function. <i>Journal of Neuroscience</i> , 2009, 29, 3579-3589.	1.7	116

#	ARTICLE	IF	CITATIONS
289	Presynaptic Defects Underlying Impaired Learning and Memory Function in Lipoprotein Lipase-Deficient Mice. <i>Journal of Neuroscience</i> , 2009, 29, 4681-4685.	1.7	65
290	Mutant Huntingtin N-terminal Fragments of Specific Size Mediate Aggregation and Toxicity in Neuronal Cells. <i>Journal of Biological Chemistry</i> , 2009, 284, 10855-10867.	1.6	124
291	Differential Susceptibility to Excitotoxic Stress in YAC128 Mouse Models of Huntington Disease between Initiation and Progression of Disease. <i>Journal of Neuroscience</i> , 2009, 29, 2193-2204.	1.7	123
292	Age-Dependent Alterations of Corticostriatal Activity in the YAC128 Mouse Model of Huntington Disease. <i>Journal of Neuroscience</i> , 2009, 29, 2414-2427.	1.7	160
293	Perceptions of genetic discrimination among people at risk for Huntington's disease: a cross sectional survey. <i>BMJ: British Medical Journal</i> , 2009, 338, b2175-b2175.	2.4	98
294	Neuronal palmitoyl acyl transferases exhibit distinct substrate specificity. <i>FASEB Journal</i> , 2009, 23, 2605-2615.	0.2	138
295	Application of principal component analysis to pharmacogenomic studies in Canada. <i>Pharmacogenomics Journal</i> , 2009, 9, 362-372.	0.9	23
296	Gender differences in expression of the human caspase-12 long variant determines susceptibility to <i>Listeria monocytogenes</i> infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 9016-9020.	3.3	53
297	Enhanced susceptibility to pancreatitis in severe hypertriglyceridaemic lipoprotein lipase-deficient mice and agonist-like function of pancreatic lipase in pancreatic cells. <i>Gut</i> , 2009, 58, 422-430.	6.1	61
298	IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. <i>Journal of Cell Biology</i> , 2009, 187, 1083-1099.	2.3	343
299	Plasma apolipoprotein AV levels in mice are positively associated with plasma triglyceride levels. <i>Journal of Lipid Research</i> , 2009, 50, 880-884.	2.0	13
300	Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 713-721.	0.9	70
301	Pharmacogenetics of Neonatal Opioid Toxicity Following Maternal Use of Codeine During Breastfeeding: A Case-Control Study. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 31-35.	2.3	284
302	Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. <i>Nature Genetics</i> , 2009, 41, 1345-1349.	9.4	287
303	Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. <i>Nature Medicine</i> , 2009, 15, 1407-1413.	15.2	381
304	Tetrabenazine. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 17-18.	21.5	47
305	The role of free fatty acids, pancreatic lipase and Ca ²⁺ signalling in injury of isolated acinar cells and pancreatitis model in lipoprotein lipase-deficient mice. <i>Acta Physiologica</i> , 2009, 195, 13-28.	1.8	73
306	CAG Expansion in the Huntington Disease Gene Is Associated with a Specific and Targetable Predisposing Haplogroup. <i>American Journal of Human Genetics</i> , 2009, 84, 351-366.	2.6	204

#	ARTICLE	IF	CITATIONS
307	Response to Falush: A Role for cis-Element Polymorphisms in HD. <i>American Journal of Human Genetics</i> , 2009, 85, 942-945.	2.6	5
308	Acute hypertriglyceridemic pancreatitis during pregnancy due to homozygous lipoprotein lipase gene mutation. <i>Clinica Chimica Acta</i> , 2009, 400, 137-138.	0.5	7
309	Absence of stearyl-CoA desaturase-1 does not promote DSS-induced acute colitis. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2009, 1791, 1166-1172.	1.2	12
310	Enhanced atherothrombotic formation after oxidative injury by FeCl ₃ to the common carotid artery in severe combined hyperlipidemic mice. <i>Biochemical and Biophysical Research Communications</i> , 2009, 385, 563-569.	1.0	7
311	Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. <i>Molecular and Cellular Neurosciences</i> , 2009, 40, 121-127.	1.0	86
312	Mouse models of Huntington disease: variations on a theme. <i>DMM Disease Models and Mechanisms</i> , 2009, 2, 123-129.	1.2	91
313	Subtype-Specific Enhancement of NMDA Receptor Currents by Mutant Huntingtin. <i>Journal of Neurochemistry</i> , 2008, 72, 1890-1898.	2.1	166
314	Re: Autopsy-proven Huntington's disease with 29 trinucleotide repeats. <i>Movement Disorders</i> , 2008, 23, 1794-1795.	2.2	20
315	Perceptions of discrimination among persons who have undergone predictive testing for Huntington's disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 320-325.	1.1	42
316	Engagement with genetic discrimination: concerns and experiences in the context of Huntington disease. <i>European Journal of Human Genetics</i> , 2008, 16, 279-289.	1.4	57
317	DNA analysis of distinct populations suggests multiple origins for the mutation causing Huntington disease. <i>Clinical Genetics</i> , 2008, 43, 286-294.	1.0	24
318	Full length mutant huntingtin is required for altered Ca ²⁺ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. <i>Neurobiology of Disease</i> , 2008, 31, 80-88.	2.1	110
319	Automated deformation analysis in the YAC128 Huntington disease mouse model. <i>NeuroImage</i> , 2008, 39, 32-39.	2.1	150
320	Cortical thickness measured from MRI in the YAC128 mouse model of Huntington's disease. <i>NeuroImage</i> , 2008, 41, 243-251.	2.1	115
321	<i>ABCA1</i> Gene Mutations, HDL Cholesterol Levels, and Risk of Ischemic Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 1997.	3.8	15
322	Spontaneous Atherosclerosis in Aged Lipoprotein Lipase-Deficient Mice With Severe Hypertriglyceridemia on a Normal Chow Diet. <i>Circulation Research</i> , 2008, 102, 250-256.	2.0	88
323	Detection of Huntington's disease decades before diagnosis: the Predict-HD study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 874-880.	0.9	696
324	Intramuscular Administration of AAV1-Lipoprotein Lipase ^{S447X} Lowers Triglycerides in Lipoprotein Lipase-Deficient Patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 2303-2304.	1.1	201

#	ARTICLE	IF	CITATIONS
325	Response to the Letter by Ebara et al. <i>Circulation Research</i> , 2008, 102, .	2.0	1
326	Polyglutamine-Modulated Striatal Calpain Activity in YAC Transgenic Huntington Disease Mouse Model: Impact on NMDA Receptor Function and Toxicity. <i>Journal of Neuroscience</i> , 2008, 28, 12725-12735.	1.7	68
327	Absence of stearyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice. <i>Journal of Lipid Research</i> , 2008, 49, 217-229.	2.0	59
328	Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus. <i>Human Molecular Genetics</i> , 2008, 17, 2390-2404.	1.4	112
329	Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. <i>Human Molecular Genetics</i> , 2008, 17, 2738-2751.	1.4	139
330	A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. <i>Journal of Experimental Medicine</i> , 2008, 205, 1869-1877.	4.2	559
331	Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. <i>Brain</i> , 2008, 132, 919-932.	3.7	135
332	Cholesterol in islet dysfunction and type 2 diabetes. <i>Journal of Clinical Investigation</i> , 2008, 118, 403-408.	3.9	125
333	Altered NMDA Receptor Trafficking in a Yeast Artificial Chromosome Transgenic Mouse Model of Huntington's Disease. <i>Journal of Neuroscience</i> , 2007, 27, 3768-3779.	1.7	112
334	NMDA Receptor Function and NMDA Receptor-Dependent Phosphorylation of Huntingtin Is Altered by the Endocytic Protein HIP1. <i>Journal of Neuroscience</i> , 2007, 27, 2298-2308.	1.7	41
335	Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. <i>Brain</i> , 2007, 130, 1732-1744.	3.7	181
336	N-Terminal Proteolysis of Full-Length Mutant Huntingtin in an Inducible PC12 Cell Model of Huntingtin's Disease. <i>Cell Cycle</i> , 2007, 6, 2970-2981.	1.3	59
337	Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. <i>Human Molecular Genetics</i> , 2007, 16, 2187-2198.	1.4	106
338	Physiologically regulated transgenic ABCA1 does not reduce amyloid burden or amyloid- β peptide levels in vivo. <i>Journal of Lipid Research</i> , 2007, 48, 914-923.	2.0	13
339	Huntingtin-Interacting Protein 1 Influences Worm and Mouse Presynaptic Function and Protects <i>Caenorhabditis elegans</i> Neurons against Mutant Polyglutamine Toxicity. <i>Journal of Neuroscience</i> , 2007, 27, 11056-11064.	1.7	61
340	Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. <i>Human Molecular Genetics</i> , 2007, 16, 1845-1861.	1.4	304
341	Mitochondrial Sensitivity and Altered Calcium Handling Underlie Enhanced NMDA-Induced Apoptosis in YAC128 Model of Huntington's Disease. <i>Journal of Neuroscience</i> , 2007, 27, 13614-13623.	1.7	111
342	Expression of LPL in Endothelial-Intact Artery Results in Lipid Deposition and Vascular Cell Adhesion Molecule-1 Upregulation in Both LPL and ApoE-Deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 197-203.	1.1	28

#	ARTICLE	IF	CITATIONS
343	Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease. <i>Neuroscience</i> , 2007, 147, 354-372.	1.1	48
344	Selective degeneration in YAC mouse models of Huntington disease. <i>Brain Research Bulletin</i> , 2007, 72, 124-131.	1.4	53
345	Pharmacogenomics and its implications for autoimmune disease. <i>Journal of Autoimmunity</i> , 2007, 28, 122-128.	3.0	27
346	Chapter 15 Juvenile amyotrophic lateral sclerosis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 82, 301-312.	1.0	42
347	When good drugs go bad. <i>Nature</i> , 2007, 446, 975-977.	13.7	246
348	Î2-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. <i>Nature Medicine</i> , 2007, 13, 340-347.	15.2	366
349	Managing genetic discrimination: Strategies used by individuals found to have the Huntington disease mutation. <i>Clinical Genetics</i> , 2007, 71, 220-231.	1.0	33
350	Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. <i>Clinical Genetics</i> , 2007, 71, 311-319.	1.0	404
351	Protective up-regulation of CK2 by mutant huntingtin in cells co-expressing NMDA receptors. <i>Journal of Neurochemistry</i> , 2007, 104, 071106220454003-???	2.1	21
352	CAG-encoded polyglutamine length polymorphism in the human genome. <i>BMC Genomics</i> , 2007, 8, 126.	1.2	78
353	Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. <i>Neurobiology of Disease</i> , 2007, 26, 189-200.	2.1	97
354	Testicular degeneration in Huntington disease. <i>Neurobiology of Disease</i> , 2007, 26, 512-520.	2.1	90
355	Verbal episodic memory declines prior to diagnosis in Huntington's disease. <i>Neuropsychologia</i> , 2007, 45, 1767-1776.	0.7	122
356	Genotypic Approaches to Therapy in Children: A National Active Surveillance Network (GATC) to Study the Pharmacogenomics of Severe Adverse Drug Reactions in Children. <i>Annals of the New York Academy of Sciences</i> , 2007, 1110, 177-192.	1.8	28
357	Mycophenolate Mofetil and Atherosclerosis: Results of Animal and Human Studies. <i>Annals of the New York Academy of Sciences</i> , 2007, 1110, 209-221.	1.8	23
358	Structural abnormalities in spermatids together with reduced sperm counts and motility underlie the reproductive defect in HIP1a ^{-/-} mice. <i>Molecular Reproduction and Development</i> , 2007, 74, 341-359.	1.0	25
359	Tu-W23:4 Hepatic ABCA1 is a key molecule in HDL cholesteryl ester metabolism in mice. <i>Atherosclerosis Supplements</i> , 2006, 7, 166-167.	1.2	0
360	Cleavage at the Caspase-6 Site Is Required for Neuronal Dysfunction and Degeneration Due to Mutant Huntingtin. <i>Cell</i> , 2006, 125, 1179-1191.	13.5	600

#	ARTICLE	IF	CITATIONS
361	Hemorheological abnormalities in lipoprotein lipase deficient mice with severe hypertriglyceridemia. <i>Biochemical and Biophysical Research Communications</i> , 2006, 341, 1066-1071.	1.0	22
362	Hippi is essential for node cilia assembly and Sonic hedgehog signaling. <i>Developmental Biology</i> , 2006, 300, 523-533.	0.9	86
363	Molecular Pathogenesis of Huntington's Disease: The Role of Excitotoxicity. , 2006, , 251-260.		1
364	Genome-wide significance for a modifier of age at neurological onset in Huntington's Disease at 6q23-24: the HD MAPS study. <i>BMC Medical Genetics</i> , 2006, 7, 71.	2.1	72
365	Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease. <i>Clinical Genetics</i> , 2006, 70, 78-79.	1.0	31
366	The genotype-phenotype correlation of hereditary multiple exostoses. <i>Clinical Genetics</i> , 2006, 70, 122-130.	1.0	68
367	Predictive testing for Huntington disease: interpretation and significance of intermediate alleles. <i>Clinical Genetics</i> , 2006, 70, 283-294.	1.0	110
368	Palmitoylation of huntingtin by HIP14 is essential for its trafficking and function. <i>Nature Neuroscience</i> , 2006, 9, 824-831.	7.1	266
369	Huntingtin inhibits caspase-3 activation. <i>EMBO Journal</i> , 2006, 25, 5896-5906.	3.5	88
370	Wild-type huntingtin protects neurons from excitotoxicity. <i>Journal of Neurochemistry</i> , 2006, 96, 1121-1129.	2.1	145
371	To be or not to be toxic: aggregations in Huntington and Alzheimer disease. <i>Trends in Genetics</i> , 2006, 22, 408-411.	2.9	32
372	FASA-57 cDNA shares no homology with coding sequence of HD gene. <i>Journal of Reproductive Immunology</i> , 2006, 69, 9-10.	0.8	0
373	Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. <i>Neurobiology of Disease</i> , 2006, 21, 392-403.	2.1	108
374	Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. <i>Neurobiology of Disease</i> , 2006, 21, 444-455.	2.1	77
375	Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. <i>Neurobiology of Disease</i> , 2006, 23, 190-197.	2.1	137
376	Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A β in plasma. <i>Neurobiology of Disease</i> , 2006, 24, 114-127.	2.1	112
377	Brain-derived neurotrophic factor does not influence age at neurologic onset of Huntington's disease. <i>Neurobiology of Disease</i> , 2006, 24, 280-285.	2.1	31
378	Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease. <i>BMC Neuroscience</i> , 2006, 7, 80.	0.8	47

#	ARTICLE	IF	CITATIONS
379	Preparing for Preventive Clinical Trials. <i>Archives of Neurology</i> , 2006, 63, 883.	4.9	292
380	Mycophenolate mofetil (MMF): Firing at the atherosclerotic plaque from different angles?. <i>Cardiovascular Research</i> , 2006, 69, 341-347.	1.8	45
381	Body weight is modulated by levels of full-length Huntingtin. <i>Human Molecular Genetics</i> , 2006, 15, 1513-1523.	1.4	101
382	Lipoprotein Lipase S447X. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1236-1245.	1.1	140
383	Mycophenolate mofetil as an immunomodulatory silver bullet in atherogenesis?. <i>Lupus</i> , 2006, 15, 11-17.	0.8	2
384	Mycophenolate mofetil and animal models. <i>Lupus</i> , 2006, 15, 27-34.	0.8	0
385	Macrophage ATP-Binding Cassette Transporter A1 Overexpression Inhibits Atherosclerotic Lesion Progression in Low-Density Lipoprotein Receptor Knockout Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 929-934.	1.1	163
386	Specific Mutations in ABCA1 Have Discrete Effects on ABCA1 Function and Lipid Phenotypes Both In Vivo and In Vitro. <i>Circulation Research</i> , 2006, 99, 389-397.	2.0	92
387	Tissue-Specific Induction of Intestinal ABCA1 Expression With a Liver X Receptor Agonist Raises Plasma HDL Cholesterol Levels. <i>Circulation Research</i> , 2006, 99, 672-674.	2.0	103
388	Mutant Huntingtin: Nuclear translocation and cytotoxicity mediated by GAPDH. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 3405-3409.	3.3	112
389	Hepatic ATP-Binding Cassette Transporter A1 Is a Key Molecule in High-Density Lipoprotein Cholesterol Ester Metabolism in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1821-1827.	1.1	33
390	Both Hepatic and Extrahepatic ABCA1 Have Discrete and Essential Functions in the Maintenance of Plasma High-Density Lipoprotein Cholesterol Levels In Vivo. <i>Circulation</i> , 2006, 114, 1301-1309.	1.6	80
391	Mitochondrial-Dependent Ca ²⁺ Handling in Huntington's Disease Striatal Cells: Effect of Histone Deacetylase Inhibitors. <i>Journal of Neuroscience</i> , 2006, 26, 11174-11186.	1.7	124
392	Als2-deficient mice exhibit disturbances in endosome trafficking associated with motor behavioral abnormalities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 9595-9600.	3.3	128
393	Variations on a Gene: Rare and Common Variants in ABCA1 and Their Impact on HDL Cholesterol Levels and Atherosclerosis. <i>Annual Review of Nutrition</i> , 2006, 26, 105-129.	4.3	139
394	Is tetrabenazine safe and effective for suppressing chorea in Huntington's disease?. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 536-537.	2.7	4
395	Correction of Feline Lipoprotein Lipase Deficiency with Adeno-Associated Virus Serotype 1-Mediated Gene Transfer of the Lipoprotein Lipase S447X Beneficial Mutation. <i>Human Gene Therapy</i> , 2006, 17, 487-499.	1.4	74
396	Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. <i>Journal of Clinical Investigation</i> , 2006, 116, 1052-1062.	3.9	447

#	ARTICLE	IF	CITATIONS
397	Correction of Feline Lipoprotein Lipase Deficiency with Adeno-Associated Virus Serotype 1-Mediated Gene Transfer of the Lipoprotein Lipase S447X Beneficial Mutation. <i>Human Gene Therapy</i> , 2006, .	1.4	0
398	Cardiovascular disease in systemic lupus erythematosus: has the time for action come?. <i>Current Opinion in Lipidology</i> , 2005, 16, 501-506.	1.2	7
399	Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. <i>Journal of Neurochemistry</i> , 2005, 94, 1087-1101.	2.1	52
400	Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. <i>Journal of Neurochemistry</i> , 2005, 95, 210-220.	2.1	96
401	Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. <i>Journal of Neurochemistry</i> , 2005, 95, 553-562.	2.1	74
402	Introduction to Social and Behavioural Research in Genetics. <i>Clinical Genetics</i> , 2005, 67, 480-480.	1.0	0
403	Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. <i>Human Molecular Genetics</i> , 2005, 14, 1569-1577.	1.4	126
404	Ethyl-EPA in Huntington disease: A double-blind, randomized, placebo-controlled trial. <i>Neurology</i> , 2005, 65, 286-292.	1.5	143
405	Huntingtin Associates with Acidic Phospholipids at the Plasma Membrane. <i>Journal of Biological Chemistry</i> , 2005, 280, 36464-36473.	1.6	133
406	Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. <i>Human Molecular Genetics</i> , 2005, 14, 3823-3835.	1.4	152
407	Complete Rescue of Lipoprotein Lipase-Deficient Mice by Somatic Gene Transfer of the Naturally Occurring LPL S447X Beneficial Mutation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2143-2150.	1.1	60
408	Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. <i>Human Molecular Genetics</i> , 2005, 14, 1379-1392.	1.4	149
409	Alternate transcripts expressed in response to diet reflect tissue-specific regulation of ABCA1. <i>Journal of Lipid Research</i> , 2005, 46, 2061-2071.	2.0	21
410	Complete functional rescue of the ABCA1 ^{-/-} mouse by human BAC transgenesis. <i>Journal of Lipid Research</i> , 2005, 46, 1113-1123.	2.0	11
411	Huntingtin Interacting Protein 1 (HIP1) Regulates Clathrin Assembly through Direct Binding to the Regulatory Region of the Clathrin Light Chain. <i>Journal of Biological Chemistry</i> , 2005, 280, 6101-6108.	1.6	101
412	The Absence of ABCA1 Decreases Soluble ApoE Levels but Does Not Diminish Amyloid Deposition in Two Murine Models of Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2005, 280, 43243-43256.	1.6	203
413	Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 11402-11407.	3.3	247
414	Disturbed Ca ²⁺ signaling and apoptosis of medium spiny neurons in Huntington's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 2602-2607.	3.3	336

#	ARTICLE	IF	CITATIONS
415	W10-IS-001 Role of ABCA1 and SR-BI in cholesterol transport and atherosclerosis. <i>Atherosclerosis Supplements</i> , 2005, 6, 46.	1.2	0
416	Gene Therapy for Lipoprotein Lipase Deficiency: Working Toward Clinical Application. <i>Human Gene Therapy</i> , 2005, 16, 1276-1286.	1.4	55
417	Cross-species characterization of the ALS2 gene and analysis of its pattern of expression in development and adulthood. <i>Neurobiology of Disease</i> , 2005, 18, 243-257.	2.1	25
418	Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. <i>Experimental Neurology</i> , 2005, 196, 266-272.	2.0	60
419	Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington's Disease. <i>Journal of Neuroscience</i> , 2005, 25, 4169-4180.	1.7	282
420	Experimental models of Huntington's disease. <i>Drug Discovery Today: Disease Models</i> , 2005, 2, 291-297.	1.2	4
421	Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. <i>Journal of Clinical Investigation</i> , 2005, 115, 1333-1342.	3.9	407
422	Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. <i>Journal of Clinical Investigation</i> , 2005, 115, 1333-1342.	3.9	225
423	Accurate Prediction of the Functional Significance of Single Nucleotide Polymorphisms and Mutations in the ABCA1 Gene. <i>PLoS Genetics</i> , 2005, 1, e83.	1.5	115
424	Gene Therapy for Lipoprotein Lipase Deficiency: Working Toward Clinical Application. <i>Human Gene Therapy</i> , 2005, .	1.4	1
425	Psychosocial effects of predictive testing for Huntington's disease. <i>Advances in Neurology</i> , 2005, 96, 226-39.	0.8	11
426	Enhanced Striatal NR2B-Containing N-Methyl-d-Aspartate Receptor-Mediated Synaptic Currents in a Mouse Model of Huntington Disease. <i>Journal of Neurophysiology</i> , 2004, 92, 2738-2746.	0.9	107
427	Deficiency of ABCA1 Impairs Apolipoprotein E Metabolism in Brain. <i>Journal of Biological Chemistry</i> , 2004, 279, 41197-41207.	1.6	321
428	Mutant Huntingtin Impairs Axonal Trafficking in Mammalian Neurons In Vivo and In Vitro. <i>Molecular and Cellular Biology</i> , 2004, 24, 8195-8209.	1.1	454
429	The ATP-binding cassette transporter 1 mediates lipid efflux from Sertoli cells and influences male fertility. <i>Journal of Lipid Research</i> , 2004, 45, 1040-1050.	2.0	86
430	Inhibition of Calpain Cleavage of Huntingtin Reduces Toxicity. <i>Journal of Biological Chemistry</i> , 2004, 279, 20211-20220.	1.6	242
431	Huntingtin Bodies Sequester Vesicle-Associated Proteins by a Polyproline-Dependent Interaction. <i>Journal of Neuroscience</i> , 2004, 24, 269-281.	1.7	157
432	A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. <i>Clinical Genetics</i> , 2004, 65, 267-277.	1.0	738

#	ARTICLE	IF	CITATIONS
433	HAP1 facilitates effects of mutant huntingtin on inositol 1,4,5-trisphosphate-induced Ca ²⁺ release in primary culture of striatal medium spiny neurons. <i>European Journal of Neuroscience</i> , 2004, 20, 1779-1787.	1.2	57
434	A homozygous HAMP mutation in a multiply consanguineous family with pseudo-dominant juvenile hemochromatosis. <i>Clinical Genetics</i> , 2004, 65, 378-383.	1.0	51
435	Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. <i>Nature Genetics</i> , 2004, 36, 77-82.	9.4	900
436	Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. <i>Cell Death and Differentiation</i> , 2004, 11, 424-438.	5.0	193
437	Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. <i>Nature</i> , 2004, 429, 75-79.	13.7	395
438	Genetic testing and Huntington's disease: issues of employment. <i>Lancet Neurology</i> , The, 2004, 3, 249-252.	4.9	25
439	Expression of matrix metalloproteinase activity in idiopathic dilated cardiomyopathy: A marker of cardiac dilatation. <i>Molecular and Cellular Biochemistry</i> , 2004, 264, 183-191.	1.4	23
440	Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16. <i>Neurogenetics</i> , 2004, 5, 109-114.	0.7	67
441	HDL deficiency and atherosclerosis: lessons from Tangier disease. <i>Journal of Internal Medicine</i> , 2004, 255, 299-301.	2.7	26
442	A case of tangier disease with a novel mutation in the c-terminal region of ATP-binding cassette transporter A1. <i>American Journal of Medical Genetics Part A</i> , 2004, 130A, 398-401.	2.4	7
443	Huntington's disease-like 2 (HDL2) in North America and Japan. <i>Annals of Neurology</i> , 2004, 56, 670-674.	2.8	105
444	Long-Term Correction of Murine Lipoprotein Lipase Deficiency with AAV1-Mediated Gene Transfer of the Naturally Occurring LPLS447X Beneficial Mutation. <i>Human Gene Therapy</i> , 2004, 15, 906-919.	1.4	67
445	A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1429-1435.	1.2	124
446	Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice. <i>Experimental Neurology</i> , 2004, 185, 26-35.	2.0	54
447	Deranged neuronal calcium signaling and Huntington disease. <i>Biochemical and Biophysical Research Communications</i> , 2004, 322, 1310-1317.	1.0	236
448	Huntingtin-Interacting Protein HIP14 Is a Palmitoyl Transferase Involved in Palmitoylation and Trafficking of Multiple Neuronal Proteins. <i>Neuron</i> , 2004, 44, 977-986.	3.8	271
449	Potential of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. <i>Molecular and Cellular Neurosciences</i> , 2004, 25, 469-479.	1.0	151
450	Identification of a Novel Gene (HSN2) Causing Hereditary Sensory and Autonomic Neuropathy Type II through the Study of Canadian Genetic Isolates. <i>American Journal of Human Genetics</i> , 2004, 74, 1064-1073.	2.6	133

#	ARTICLE	IF	CITATIONS
451	O1-03-07 ABCA1 modulates APOE levels in brain and plasma. <i>Neurobiology of Aging</i> , 2004, 25, S15-S16.	1.5	1
452	Disruption of the endocytic protein HIP1 results in neurological deficits and decreased AMPA receptor trafficking. <i>EMBO Journal</i> , 2003, 22, 3254-3266.	3.5	102
453	Predictive testing for Huntington's disease: a universal model?. <i>Lancet Neurology</i> , The, 2003, 2, 141-142.	4.9	31
454	Huntingtin proteolysis in Huntington disease. <i>Clinical Neuroscience Research</i> , 2003, 3, 129-139.	0.8	9
455	Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. , 2003, 119A, 279-282.		146
456	CAG repeat polymorphisms in KCNN3 (HSCa3) and PPP2R2B show no association or linkage to schizophrenia. , 2003, 116B, 45-50.		10
457	An ALS2 gene mutation causes hereditary spastic paraplegia in a Pakistani kindred. <i>Annals of Neurology</i> , 2003, 53, 144-145.	2.8	97
458	Predictive, pre-natal and diagnostic genetic testing for Huntington's disease: the experience in Canada from 1987 to 2000. <i>Clinical Genetics</i> , 2003, 63, 462-475.	1.0	134
459	The first nonsense mutation in alsin results in a homogeneous phenotype of infantile-onset ascending spastic paralysis with bulbar involvement in two siblings. <i>Clinical Genetics</i> , 2003, 64, 210-215.	1.0	83
460	Psychological consequences and predictors of adverse events in the first 5 years after predictive testing for Huntington's disease. <i>Clinical Genetics</i> , 2003, 64, 300-309.	1.0	107
461	Predictive testing for persons at risk for homozygosity for CAG expansion in the Huntington disease gene. <i>Clinical Genetics</i> , 2003, 64, 524-525.	1.0	11
462	Depletion of wild-type huntingtin in mouse models of neurologic diseases. <i>Journal of Neurochemistry</i> , 2003, 87, 101-106.	2.1	97
463	Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. <i>Nature Genetics</i> , 2003, 35, 76-83.	9.4	807
464	Clarity is essential when using Nucleotide number systems. <i>Atherosclerosis</i> , 2003, 170, 349.	0.4	0
465	Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. <i>Neurobiology of Aging</i> , 2003, 24, 1113-1121.	1.5	97
466	Caudate volume as an outcome measure in clinical trials for Huntington's disease: a pilot study. <i>Brain Research Bulletin</i> , 2003, 62, 137-141.	1.4	42
467	Heterozygosity for ABCA1 gene mutations: effects on enzymes, apolipoproteins and lipoprotein particle size. <i>Atherosclerosis</i> , 2003, 171, 311-319.	0.4	19
468	Skewed X-Chromosome Inactivation Is Associated with Trisomy in Women Ascertained on the Basis of Recurrent Spontaneous Abortion or Chromosomally Abnormal Pregnancies. <i>American Journal of Human Genetics</i> , 2003, 72, 399-407.	2.6	75

#	ARTICLE	IF	CITATIONS
469	A Genome Scan for Modifiers of Age at Onset in Huntington Disease: The HD MAPS Study. <i>American Journal of Human Genetics</i> , 2003, 73, 682-687.	2.6	148
470	Allelic variation in the promoter region of the LDL receptor gene: analysis of an African-specific variant in the FP2 cis-acting regulatory element. <i>Molecular and Cellular Probes</i> , 2003, 17, 175-181.	0.9	2
471	Huntingtin and Huntingtin-Associated Protein 1 Influence Neuronal Calcium Signaling Mediated by Inositol-(1,4,5) Triphosphate Receptor Type 1. <i>Neuron</i> , 2003, 39, 227-239.	3.8	442
472	Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. <i>Brain</i> , 2003, 126, 946-955.	3.7	173
473	Restoration of Endothelial Function by Increasing High-Density Lipoprotein in Subjects With Isolated Low High-Density Lipoprotein. <i>Circulation</i> , 2003, 107, 2944-2948.	1.6	283
474	ABCA1 Is Essential for Efficient Basolateral Cholesterol Efflux during the Absorption of Dietary Cholesterol in Chickens. <i>Journal of Biological Chemistry</i> , 2003, 278, 13356-13366.	1.6	105
475	Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1. <i>Journal of Lipid Research</i> , 2003, 44, 1470-1480.	2.0	85
476	A Role for Epsin N-terminal Homology/AP180 N-terminal Homology (ENTH/ANTH) Domains in Tubulin Binding. <i>Journal of Biological Chemistry</i> , 2003, 278, 28823-28830.	1.6	26
477	Nuclear Localization of a Non-caspase Truncation Product of Atrophin-1, with an Expanded Polyglutamine Repeat, Increases Cellular Toxicity. <i>Journal of Biological Chemistry</i> , 2003, 278, 13047-13055.	1.6	78
478	Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. <i>Human Molecular Genetics</i> , 2003, 12, 1555-1567.	1.4	713
479	Efflux and Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1322-1332.	1.1	231
480	The role of the ABCA1 transporter and cholesterol efflux in familial hypoalphalipoproteinemia. <i>Journal of Lipid Research</i> , 2003, 44, 1251-1255.	2.0	40
481	Mutation Screening of the ALS2 Gene in Sporadic and Familial Amyotrophic Lateral Sclerosis. <i>Archives of Neurology</i> , 2003, 60, 1768.	4.9	40
482	Targeted disruption of Huntingtin-associated protein-1 (Hap1) results in postnatal death due to depressed feeding behavior. <i>Human Molecular Genetics</i> , 2002, 11, 945-959.	1.4	73
483	HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. <i>Human Molecular Genetics</i> , 2002, 11, 2815-2828.	1.4	189
484	Protein Kinase A Site-specific Phosphorylation Regulates ATP-binding Cassette A1 (ABCA1)-mediated Phospholipid Efflux. <i>Journal of Biological Chemistry</i> , 2002, 277, 41835-41842.	1.6	116
485	Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. <i>Human Molecular Genetics</i> , 2002, 11, 1939-1951.	1.4	129
486	Identification and functional analysis of a naturally occurring E89K mutation in the ABCA1 gene of the WHAM chicken. <i>Journal of Lipid Research</i> , 2002, 43, 1610-1617.	2.0	49

#	ARTICLE	IF	CITATIONS
487	HIP1 and HIP12 Display Differential Binding to F-actin, AP2, and Clathrin. <i>Journal of Biological Chemistry</i> , 2002, 277, 19897-19904.	1.6	97
488	Truncation mutations in ABCA1 suppress normal upregulation of full-length ABCA1 by 9-cis-retinoic acid and 22-R-hydroxycholesterol. <i>Journal of Lipid Research</i> , 2002, 43, 1939-1949.	2.0	26
489	Expression and Functional Analyses of Novel Mutations of ATP-Binding Cassette Transporter-1 in Japanese Patients with High-Density Lipoprotein Deficiency. <i>Biochemical and Biophysical Research Communications</i> , 2002, 290, 713-721.	1.0	30
490	Relationship between stearyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. <i>Journal of Lipid Research</i> , 2002, 43, 1899-1907.	2.0	318
491	Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. <i>Lancet, The</i> , 2002, 359, 37-41.	6.3	186
492	Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease. <i>Neuron</i> , 2002, 33, 849-860.	3.8	553
493	Caspase Cleavage of Mutant Huntingtin Precedes Neurodegeneration in Huntington's Disease. <i>Journal of Neuroscience</i> , 2002, 22, 7862-7872.	1.7	344
494	Striatal neurochemical changes in transgenic models of Huntington's disease. <i>Journal of Neuroscience Research</i> , 2002, 68, 716-729.	1.3	88
495	High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia. <i>Clinical Genetics</i> , 2002, 60, 198-205.	1.0	82
496	ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels. <i>Clinical Genetics</i> , 2002, 61, 115-125.	1.0	95
497	ABCA1 mRNA and Protein Distribution Patterns Predict Multiple Different Roles and Levels of Regulation. <i>Laboratory Investigation</i> , 2002, 82, 273-283.	1.7	265
498	Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. <i>Nature Cell Biology</i> , 2002, 4, 95-105.	4.6	274
499	Mutant DNA-binding domain of HSF4 is associated with autosomal dominant lamellar and Marner cataract. <i>Nature Genetics</i> , 2002, 31, 276-278.	9.4	229
500	Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy. <i>Nature Genetics</i> , 2002, 32, 326-330.	9.4	409
501	Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. <i>Nature Neuroscience</i> , 2002, 5, 731-736.	7.1	925
502	Structural and functional consequences of missense mutations in exon 5 of the lipoprotein lipase gene. <i>Journal of Lipid Research</i> , 2002, 43, 398-406.	2.0	30
503	Increased ABCA1 activity protects against atherosclerosis. <i>Journal of Clinical Investigation</i> , 2002, 110, 35-42.	3.9	216
504	Increased ABCA1 activity protects against atherosclerosis. <i>Journal of Clinical Investigation</i> , 2002, 110, 35-42.	3.9	121

#	ARTICLE	IF	CITATIONS
505	The factor structure for positive and negative symptoms in South African Xhosa patients with schizophrenia. <i>Schizophrenia Research</i> , 2001, 47, 149-157.	1.1	42
506	Common mutations in the lipoprotein lipase gene (LPL): effects on HDL-cholesterol levels in a Chinese Canadian population. <i>Atherosclerosis</i> , 2001, 156, 401-407.	0.4	35
507	Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease. <i>Science</i> , 2001, 293, 493-498.	6.0	1,191
508	Cloning and Characterization of Three Novel Genes, ALS2CR1, ALS2CR2, and ALS2CR3, in the Juvenile Amyotrophic Lateral Sclerosis (ALS2) Critical Region at Chromosome 2q33-q34: Candidate Genes for ALS2. <i>Genomics</i> , 2001, 71, 200-213.	1.3	46
509	Mutant Huntingtin Enhances Excitotoxic Cell Death. <i>Molecular and Cellular Neurosciences</i> , 2001, 17, 41-53.	1.0	173
510	A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. <i>Nature Genetics</i> , 2001, 29, 166-173.	9.4	635
511	Measurement of Mutational Flow Implies Both a High New-Mutation Rate for Huntington Disease and Substantial Underascertainment of Late-Onset Cases. <i>American Journal of Human Genetics</i> , 2001, 68, 373-385.	2.6	64
512	Wild-Type Huntingtin Reduces the Cellular Toxicity of Mutant Huntingtin In Vivo. <i>American Journal of Human Genetics</i> , 2001, 68, 313-324.	2.6	210
513	Onset and pre-onset studies to define the Huntington's disease natural history. <i>Brain Research Bulletin</i> , 2001, 56, 233-238.	1.4	43
514	Expanded polyglutamines in <i>Caenorhabditis elegans</i> cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 13318-13323.	3.3	199
515	The "flap" endonuclease gene FEN1 is excluded as a candidate gene implicated in the CAG repeat expansion underlying Huntington disease. <i>Clinical Genetics</i> , 2001, 59, 122-127.	1.0	35
516	The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease. <i>Clinical Genetics</i> , 2001, 60, 293-300.	1.0	49
517	NMDA receptor function in mouse models of Huntington disease. <i>Journal of Neuroscience Research</i> , 2001, 66, 525-539.	1.3	246
518	Familial influence on age of onset among siblings with Huntington disease. <i>American Journal of Medical Genetics Part A</i> , 2001, 105, 399-403.	2.4	92
519	addendum: A one-hit model of cell death in inherited neuronal degenerations. <i>Nature</i> , 2001, 409, 542-542.	13.7	3
520	Human ABCA1 BAC Transgenic Mice Show Increased High Density Lipoprotein Cholesterol and ApoAI-dependent Efflux Stimulated by an Internal Promoter Containing Liver X Receptor Response Elements in Intron 1. <i>Journal of Biological Chemistry</i> , 2001, 276, 33969-33979.	1.6	176
521	HIP1 Functions in Clathrin-mediated Endocytosis through Binding to Clathrin and Adaptor Protein 2. <i>Journal of Biological Chemistry</i> , 2001, 276, 39271-39276.	1.6	174
522	Double-stranded RNA-dependent protein kinase, PKR, binds preferentially to Huntington's disease (HD) transcripts and is activated in HD tissue. <i>Human Molecular Genetics</i> , 2001, 10, 1531-1538.	1.4	103

#	ARTICLE	IF	CITATIONS
523	Clinical markers of early disease in persons near onset of Huntington's disease. <i>Neurology</i> , 2001, 57, 658-662.	1.5	197
524	Common Genetic Variation in <i>ABCA1</i> Is Associated With Altered Lipoprotein Levels and a Modified Risk for Coronary Artery Disease. <i>Circulation</i> , 2001, 103, 1198-1205.	1.6	280
525	Maternal expression of functional lipoprotein lipase and effects on body fat mass and body condition scores of mature cats with lipoprotein lipase deficiency. <i>American Journal of Veterinary Research</i> , 2001, 62, 264-269.	0.3	11
526	Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. <i>Journal of Lipid Research</i> , 2001, 42, 1717-1726.	2.0	244
527	The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 1811-6.	3.3	89
528	Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency. <i>Current Opinion in Lipidology</i> , 2000, 11, 117-122.	1.2	111
529	Caspases and neurodegeneration: on the cutting edge of new therapeutic approaches. <i>Clinical Genetics</i> , 2000, 57, 1-10.	1.0	119
530	A one-hit model of cell death in inherited neuronal degenerations. <i>Nature</i> , 2000, 406, 195-199.	13.7	294
531	Michael Smith (1932-2000). <i>Nature</i> , 2000, 408, 786-786.	13.7	0
532	HIP12 is a non-proapoptotic member of a gene family including HIP1, an interacting protein with huntingtin. <i>Mammalian Genome</i> , 2000, 11, 1006-1015.	1.0	47
533	Wild-Type Huntingtin Protects from Apoptosis Upstream of Caspase-3. <i>Journal of Neuroscience</i> , 2000, 20, 3705-3713.	1.7	349
534	Huntingtin Interacting Protein 1 Induces Apoptosis via a Novel Caspase-dependent Death Effector Domain. <i>Journal of Biological Chemistry</i> , 2000, 275, 41299-41308.	1.6	108
535	Phenotypic Correction of Feline Lipoprotein Lipase Deficiency by Adenoviral Gene Transfer. <i>Human Gene Therapy</i> , 2000, 11, 21-32.	1.4	37
536	Huntingtin is required for normal hematopoiesis. <i>Human Molecular Genetics</i> , 2000, 9, 387-394.	1.4	40
537	Familial Aggregation of Psychotic Symptoms in Huntington's Disease. <i>American Journal of Psychiatry</i> , 2000, 157, 1955-1959.	4.0	61
538	Lipoprotein Lipase Activity Is Associated With Severity of Angina Pectoris. <i>Circulation</i> , 2000, 102, 1629-1633.	1.6	52
539	Inhibiting Caspase Cleavage of Huntingtin Reduces Toxicity and Aggregate Formation in Neuronal and Nonneuronal Cells. <i>Journal of Biological Chemistry</i> , 2000, 275, 19831-19838.	1.6	320
540	Human huntingtin-associated protein (HAP-1) gene: genomic organisation and an intragenic polymorphism. <i>Gene</i> , 2000, 254, 181-187.	1.0	6

#	ARTICLE	IF	CITATIONS
541	Predictive testing for Huntington's disease: the calm after the storm. <i>Lancet, The</i> , 2000, 356, 1944-1945.	6.3	43
542	Huntington disease: new insights on the role of huntingtin cleavage. , 2000, , 1-17.		28
543	Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. <i>Journal of Lipid Research</i> , 2000, 41, 521-531.	2.0	83
544	Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. <i>Journal of Clinical Investigation</i> , 2000, 106, 1263-1270.	3.9	295
545	Mutations du gène de l'ATP binding cassette-1 (ABC1) dans la maladie de Tangier et la déficience familiale en HDL. <i>Medecine/Sciences</i> , 2000, 16, 421.	0.0	0
546	An Actin-Binding Protein of the Sla2/Huntingtin Interacting Protein 1 Family Is a Novel Component of Clathrin-Coated Pits and Vesicles. <i>Journal of Cell Biology</i> , 1999, 147, 1503-1518.	2.3	202
547	Recent Insights into the Molecular Pathogenesis of Huntington Disease. <i>Seminars in Neurology</i> , 1999, 19, 385-395.	0.5	50
548	Cleavage of Atrophin-1 at Caspase Site Aspartic Acid 109 Modulates Cytotoxicity. <i>Journal of Biological Chemistry</i> , 1999, 274, 8730-8736.	1.6	99
549	A Frequent Mutation in the Lipoprotein Lipase Gene (D9N) Deteriorates the Biochemical and Clinical Phenotype of Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 2708-2713.	1.1	32
550	In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease. <i>Human Molecular Genetics</i> , 1999, 8, 25-33.	1.4	79
551	Accurate determination of the number of CAG repeats in the Huntington disease gene using a sequence-specific internal DNA standard. <i>Clinical Genetics</i> , 1999, 55, 198-202.	1.0	32
552	A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study. <i>Clinical Genetics</i> , 1999, 55, 450-454.	1.0	109
553	Two common mutations (D9N, N291S) in lipoprotein lipase: a cumulative analysis of their influence on plasma lipids and lipoproteins in men and women. <i>Clinical Genetics</i> , 1999, 56, 297-305.	1.0	46
554	Lipid and lipoprotein analysis of cats with lipoprotein lipase deficiency. <i>European Journal of Clinical Investigation</i> , 1999, 29, 17-26.	1.7	32
555	Kennedy's Disease. <i>Journal of Neurochemistry</i> , 1999, 72, 185-195.	2.1	211
556	Life Without Huntingtin. Normal Differentiation into Functional Neurons. <i>Journal of Neurochemistry</i> , 1999, 72, 1009-1018.	2.1	37
557	Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. <i>Nature Genetics</i> , 1999, 22, 336-345.	9.4	1,609
558	Chromosomal localization of the Huntingtin Associated Protein (HAP-1) gene in mouse and humans with radiation hybrid and interspecific backcross mapping. <i>Mammalian Genome</i> , 1999, 10, 397-398.	1.0	5

#	ARTICLE	IF	CITATIONS
559	Genomic organization of the human caspase-9 gene on Chromosome 1p36.1-p36.3. <i>Mammalian Genome</i> , 1999, 10, 757-760.	1.0	14
560	Neuronal degeneration in the basal ganglia and loss of pallido-subthalamic synapses in mice with targeted disruption of the Huntington's disease gene. <i>Brain Research</i> , 1999, 818, 468-479.	1.1	77
561	A Worldwide Assessment of the Frequency of Suicide, Suicide Attempts, or Psychiatric Hospitalization after Predictive Testing for Huntington Disease. <i>American Journal of Human Genetics</i> , 1999, 64, 1293-1304.	2.6	271
562	Forskolin and dopamine D1 receptor activation increase Huntingtin's association with endosomes in immortalized neuronal cells of striatal origin. <i>Neuroscience</i> , 1999, 89, 1159-1167.	1.1	45
563	A YAC Mouse Model for Huntington's Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration. <i>Neuron</i> , 1999, 23, 181-192.	3.8	789
564	Mutations in the ABC 1 gene in familial HDL deficiency with defective cholesterol efflux. <i>Lancet</i> , The, 1999, 354, 1341-1346.	6.3	345
565	Evidence for both nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 1999, 354, 1047-1055.	1.8	29
566	Effect of concurrent LDL receptor gene and LPL gene mutations on LDL particles size, density and lipid composition. <i>Atherosclerosis</i> , 1999, 144, 175.	0.4	0
567	A Yeast Artificial Chromosome-Based Physical Map of the Juvenile Amyotrophic Lateral Sclerosis (ALS2) Critical Region on Human Chromosome 2q33-q34. <i>Genomics</i> , 1999, 55, 106-112.	1.3	18
568	Lipoprotein lipase activity is decreased in a large cohort of patients with coronary artery disease and is associated with changes in lipids and lipoproteins. <i>Journal of Lipid Research</i> , 1999, 40, 735-743.	2.0	79
569	Cell death attenuation by 'Usurpin', a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex. <i>Cell Death and Differentiation</i> , 1998, 5, 271-288.	5.0	293
570	Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. <i>Nature Genetics</i> , 1998, 18, 150-154.	9.4	456
571	Compound heterozygosity for frameshift mutations in the gene for lipoprotein lipase in a patient with early-onset chylomicronemia. <i>Human Mutation</i> , 1998, 11, S141-S144.	1.1	5
572	Dyslipidemias associated with heterozygous lipoprotein lipase mutations in the French-Canadian population. <i>Human Mutation</i> , 1998, 11, S148-S153.	1.1	14
573	Ile225Thr loop mutation in the lipoprotein lipase (LPL) gene is a de novo event. , 1998, 78, 313-316.		12
574	Gene structure and map location of the murine homolog of the Huntington-associated protein, Hap1. <i>Mammalian Genome</i> , 1998, 9, 565-570.	1.0	26
575	The new Clinical Genetics: towards the millennium. <i>Clinical Genetics</i> , 1998, 53, 1-2.	1.0	1
576	A novel Glu421Lys substitution in the lipoprotein lipase gene in pregnancy-induced hypertriglyceridemic pancreatitis. <i>Clinica Chimica Acta</i> , 1998, 269, 1-12.	0.5	40

#	ARTICLE	IF	CITATIONS
577	A Huntington Diseaseâ€œLike Neurodegenerative Disorder Maps to Chromosome 20p. American Journal of Human Genetics, 1998, 63, 1431-1438.	2.6	64
578	The Influence of Huntingtin Protein Size on Nuclear Localization and Cellular Toxicity. Journal of Cell Biology, 1998, 141, 1097-1105.	2.3	300
579	A Common Mutation in the Lipoprotein Lipase Gene (N291S) Alters the Lipoprotein Phenotype and Risk for Cardiovascular Disease in Patients With Familial Hypercholesterolemia. Circulation, 1998, 97, 729-735.	1.6	80
580	Phenotypic Variation in Heterozygous Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 309-315.	1.1	128
581	Caspase Cleavage of Gene Products Associated with Triplet Expansion Disorders Generates Truncated Fragments Containing the Polyglutamine Tract. Journal of Biological Chemistry, 1998, 273, 9158-9167.	1.6	499
582	The Asn9 variant of lipoprotein lipase is associated with the â€”93G promoter mutation and an increased risk of coronary artery disease. Clinical Genetics, 1998, 53, 27-33.	1.0	5
583	The fatal attraction of polyglutamineâ€œcontaining proteins. Clinical Genetics, 1998, 53, 233-242.	1.0	26
584	The Asn9 variant of lipoprotein lipase is associated with the -93G promoter mutation and an increased risk of coronary artery disease. Clinical Genetics, 1998, 53, 27-33.	1.0	41
585	Contribution of DNA Sequence and CAG Size to Mutation Frequencies of Intermediate Alleles for Huntington Disease: Evidence from Single Sperm Analyses. Human Molecular Genetics, 1997, 6, 301-309.	1.4	116
586	Pathological association and dissociation of functional systems in multiple sclerosis and Huntington's disease. Journal of Clinical and Experimental Neuropsychology, 1997, 19, 63-76.	0.8	10
587	Assessment of French patients with LPL deficiency for French Canadian mutations.. Journal of Medical Genetics, 1997, 34, 672-675.	1.5	10
588	Segments in the C-terminal Folding Domain of Lipoprotein Lipase Important for Binding to the Low Density Lipoprotein Receptor-related Protein and to Heparan Sulfate Proteoglycans. Journal of Biological Chemistry, 1997, 272, 5821-5827.	1.6	48
589	Rethinking Genotype and Phenotype Correlations in Polyglutamine Expansion Disorders. Human Molecular Genetics, 1997, 6, 2005-2010.	1.4	132
590	Of molecular interactions, mice and mechanisms. Current Opinion in Neurology, 1997, 10, 291-298.	1.8	44
591	Efficient Adenovirus-Mediated Ectopic Gene Expression of Human Lipoprotein Lipase in Human Hepatic (HepG2) Cells. Human Gene Therapy, 1997, 8, 205-214.	1.4	11
592	Familial defective apolipoprotein B-100 in hypercholesterolemic Chinese Canadians: identification of a unique haplotype of the apolipoprotein B-100 allele. Atherosclerosis, 1997, 135, 181-185.	0.4	6
593	1.W05.3 Common mutations in the lipoprotein lipase gene influence plasma lipids and prevalence of coronary heart disease. Atherosclerosis, 1997, 134, 12.	0.4	0
594	1.P.265 Phenotypic variation in familial hypercholesterolemia: A comparison of Chinese patients heterozygous for the same or similar mutations in the low density lipoprotein-receptor gene living in China or Canada. Atherosclerosis, 1997, 134, 72.	0.4	0

#	ARTICLE	IF	CITATIONS
595	2.W13.1 Molecular genetics as tools to redefine the clinics of lipoprotein disorders: The example of lipoprotein lipase deficiency. <i>Atherosclerosis</i> , 1997, 134, 110.	0.4	0
596	Risk Reversals in Predictive Testing for Huntington Disease. <i>American Journal of Human Genetics</i> , 1997, 61, 945-952.	2.6	34
597	Ethnic Variation and In Vivo Effects of the α^{93} Promoter Variant in the Lipoprotein Lipase Gene. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 2672-2678.	1.1	40
598	Correction of Hypertriglyceridemia and Impaired Fat Tolerance in Lipoprotein Lipase-Deficient Mice by Adenovirus-Mediated Expression of Human Lipoprotein Lipase. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 2532-2539.	1.1	58
599	HIP1, a human homologue of <i>S. cerevisiae</i> Sla2p, interacts with membrane-associated huntingtin in the brain. <i>Nature Genetics</i> , 1997, 16, 44-53.	9.4	353
600	Toward Understanding the Molecular Pathology of Huntington's Disease. <i>Brain Pathology</i> , 1997, 7, 979-1002.	2.1	69
601	Localization of the cell death genes CPP32 and Mch-2 to human Chromosome 4q. <i>Mammalian Genome</i> , 1997, 8, 56-59.	1.0	13
602	Interleukin-1 β -converting enzyme (ICE) and related cell death genes ICe1-II and ICe1-III map to the same PAC clone at band 11q22.2-22.3. <i>Mammalian Genome</i> , 1997, 8, 611-613.	1.0	11
603	Dilemmas of anonymous predictive testing for Huntington disease: Privacy vs. optimal care. , 1997, 71, 197-201.		18
604	A single Ser259Arg mutation in the gene for lipoprotein lipase causes chylomicronemia in Moroccans of Berber ancestry. , 1997, 10, 179-185.		7
605	Differences in the Phenotype Between Children With Familial Defective Apolipoprotein B-100 and Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 826-833.	1.1	30
606	Genetic Variant Showing a Positive Interaction With β -Blocking Agents With a Beneficial Influence on Lipoprotein Lipase Activity, HDL Cholesterol, and Triglyceride Levels in Coronary Artery Disease Patients. <i>Circulation</i> , 1997, 95, 2628-2635.	1.6	117
607	Gene-based therapeutic strategies for Human Lipoprotein Lipase (LPL) deficiency: Rationale and prospects for alteration of atherogenic risk. <i>Transfusion Science</i> , 1996, 17, 79-87.	0.6	1
608	Huntington disease: new insights into the relationship between CAG expansion and disease. <i>Human Molecular Genetics</i> , 1996, 5, 1431-1435.	1.4	60
609	Compound heterozygosity for a known and a novel defect in the lipoprotein lipase gene (Asp250 ? Asn;) Tj ETQq1 1 0.784314 rgBT /Ov 189-195.	0.6	13
610	Common sequence variants of lipoprotein lipase: standardized studies of in vitro expression and catalytic function. <i>Lipids and Lipid Metabolism</i> , 1996, 1302, 159-166.	2.6	101
611	A New Mutation Destroying Disulphide Bridging in the C-Terminal Domain of Lipoprotein Lipase. <i>Biochemical and Biophysical Research Communications</i> , 1996, 227, 189-194.	1.0	29
612	Update on genetics of Huntington's disease: availability of direct and accurate predictive test. <i>Italian Journal of Neurological Sciences</i> , 1996, 17, 185-187.	0.1	4

#	ARTICLE	IF	CITATIONS
613	Patients' rights to laboratory data: Trinucleotide repeat length in Huntington disease. , 1996, 62, 6-9.		15
614	Auxiliary-directed peroxidation of 1,4-dienes. Tetrahedron, 1996, 52, 12381-12398.	1.0	8
615	Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nature Genetics, 1996, 13, 442-449.	9.4	545
616	Absence of Disease Phenotype and Intergenerational Stability of the Cag Repeat in Transgenic Mice Expressing the Human Huntington Disease Transcript. Human Molecular Genetics, 1996, 5, 177-185.	1.4	109
617	Adverse psychological events occurring in the first year after predictive testing for Huntington's disease. The Canadian Collaborative Study Predictive Testing.. Journal of Medical Genetics, 1996, 33, 856-862.	1.5	55
618	Premature Atherosclerosis in Patients with Familial Chylomicronemia Caused by Mutations in the Lipoprotein Lipase Gene. New England Journal of Medicine, 1996, 335, 848-854.	13.9	286
619	Huntingtin Is Ubiquitinated and Interacts with a Specific Ubiquitin-conjugating Enzyme. Journal of Biological Chemistry, 1996, 271, 19385-19394.	1.6	313
620	Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype. Human Molecular Genetics, 1996, 5, 1875-1885.	1.4	94
621	The Asp ⁹ Asn Mutation in the Lipoprotein Lipase Gene Is Associated With Increased Progression of Coronary Atherosclerosis. Circulation, 1996, 94, 1913-1918.	1.6	103
622	A mutation in the lipoprotein lipase gene is the molecular basis of chylomicronemia in a colony of domestic cats.. Journal of Clinical Investigation, 1996, 97, 1257-1266.	3.9	68
623	Hereditary Late-Onset Chorea Without Significant Dementia. Neurology, 1995, 45, 443-447.	1.5	56
624	Are we all of one mind? Clinicians' and patients' opinions regarding the development of a service protocol for predictive testing for Huntington disease. American Journal of Medical Genetics Part A, 1995, 58, 59-69.	2.4	24
625	Mapping of the gonadotropin-releasing hormone (GnRH) receptor gene to human Chromosome 4q21.2 by fluorescence in situ hybridization. Mammalian Genome, 1995, 6, 309-310.	1.0	10
626	A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nature Genetics, 1995, 10, 28-34.	9.4	235
627	Many roads lead to atheroma. Nature Medicine, 1995, 1, 22-23.	15.2	23
628	Mutations in the Gene for Lipoprotein Lipase. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1704-1712.	1.1	39
629	Patients With ApoE3 Deficiency (E2/2, E3/2, and E4/2) Who Manifest With Hyperlipidemia Have Increased Frequency of an Asn 291Ser Mutation in the Human LPL Gene. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1695-1703.	1.1	59
630	Retroviral-Mediated Gene Transfer and Expression of Human Lipoprotein Lipase in Somatic Cells. Human Gene Therapy, 1995, 6, 853-863.	1.4	7

#	ARTICLE	IF	CITATIONS
631	Ancestral differences in the distribution of the \hat{I}^{2642} glutamic acid polymorphism is associated with varying CAG repeat lengths on normal chromosomes: insights into the genetic evolution of Huntington disease. <i>Human Molecular Genetics</i> , 1995, 4, 207-214.	1.4	74
632	Increased instability of intermediate alleles in families with sporadic Huntington disease compared to similar sized intermediate alleles in the general population. <i>Human Molecular Genetics</i> , 1995, 4, 1911-1918.	1.4	129
633	Somatic mosaicism in sperm is associated with intergenerational (CAG) _n changes in Huntington disease. <i>Human Molecular Genetics</i> , 1995, 4, 189-195.	1.4	74
634	A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidemia. <i>Human Molecular Genetics</i> , 1995, 4, 1543-1549.	1.4	80
635	Origins and evolution of huntington disease chromosomes. <i>Experimental Neurology</i> , 1995, 4, 239-244.	1.7	25
636	Structural analysis of the 5' region of mouse and human huntington disease genes reveals conservation of putative promoter region and di- and trinucleotide polymorphisms. <i>Genomics</i> , 1995, 25, 707-715.	1.3	41
637	Genomic organization of the human \hat{I}^{\pm} -adducin gene and its alternately spliced isoforms. <i>Genomics</i> , 1995, 25, 93-99.	1.3	37
638	Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. <i>Cell</i> , 1995, 81, 811-823.	13.5	758
639	Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients. <i>Atherosclerosis</i> , 1995, 116, 153-162.	0.4	19
640	Sequence of the murine Huntington disease gene: evidence for conservation, and polymorphism in a triplet (CCG) repeat alternate splicing. <i>Human Molecular Genetics</i> , 1994, 3, 85-92.	1.4	87
641	Analysis of DNA changes in the LPL gene in patients with familial combined hyperlipidemia.. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1994, 14, 1250-1257.	3.8	72
642	Sequence of the murine Huntington disease gene: evidence for conservation, alternate splicing and polymorphism in a triplet (CCG) repeat. <i>Human Molecular Genetics</i> , 1994, 3, 530-530.	1.4	30
643	Apolipoprotein CII-Padova (Tyr37->stop) as a cause of chylomicronaemia in an Italian kindred from Siciliana.. <i>Journal of Medical Genetics</i> , 1994, 31, 622-626.	1.5	7
644	Homozygosity for a mutation in the lipoprotein lipase gene (Gly139?Ser) causes chylomicronaemia in a boy of Spanish descent. <i>Human Genetics</i> , 1994, 93, 339-343.	1.8	10
645	Recurrent missense mutations at the first and second base of codon Arg243 in human lipoprotein lipase in patients of different ancestries. <i>Human Mutation</i> , 1994, 3, 52-58.	1.1	25
646	Regional cerebral glucose metabolism in huntington's disease: A statistical investigation. <i>Human Brain Mapping</i> , 1994, 2, 95-102.	1.9	2
647	U-type exchange in a paracentric inversion as a possible mechanism of origin of an inverted tandem duplication of chromosome 8. <i>American Journal of Medical Genetics Part A</i> , 1994, 49, 384-387.	2.4	31
648	A CCG repeat polymorphism adjacent to the CAG repeat in the Huntington disease gene: implications for diagnostic accuracy and predictive testing. <i>Human Molecular Genetics</i> , 1994, 3, 65-67.	1.4	157

#	ARTICLE	IF	CITATIONS
649	Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. <i>American Journal of Cardiology</i> , 1994, 73, 339-345.	0.7	78
650	Somatic and gonadal mosaicism of the Huntington disease gene CAG repeat in brain and sperm. <i>Nature Genetics</i> , 1994, 6, 409-414.	9.4	383
651	A Worldwide Study of the Huntington's Disease Mutation: The Sensitivity and Specificity of Measuring CAG Repeats. <i>New England Journal of Medicine</i> , 1994, 330, 1401-1406.	13.9	563
652	Precise Mapping of the Brain α -Adrenergic Receptor Gene within Chromosome 4p16. <i>Genomics</i> , 1994, 19, 298-302.	1.3	25
653	The Murine Homologues of the Huntington Disease Gene (Hdh) and the α -Adducin Gene (Add1) Map to Mouse Chromosome 5 within a Region of Conserved Synteny with Human Chromosome 4p16.3. <i>Genomics</i> , 1994, 22, 198-201.	1.3	21
654	Murine α -Iduronidase: cDNA Isolation and Expression. <i>Genomics</i> , 1994, 24, 311-316.	1.3	30
655	DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence. <i>Human Molecular Genetics</i> , 1994, 3, 2103-2114.	1.4	178
656	Issues in Molecular Genetic Testing of Individuals with Suspected Early-onset Familial Alzheimer's Disease. <i>Alzheimer Disease and Associated Disorders</i> , 1994, 8, 116-125.	0.6	13
657	The molecular genetics of Huntington's disease. <i>Current Opinion in Neurology</i> , 1994, 7, 325-332.	1.8	27
658	Gene environment interaction and plasma triglyceride levels: the crucial role of lipoprotein lipase. <i>Clinical Genetics</i> , 1994, 46, 15-18.	1.0	14
659	Normal CAG repeat length in the Huntington's disease gene in senile chorea. <i>Neurology</i> , 1994, 44, 2183-2183.	1.5	25
660	Reply to Dr. Kessler. <i>American Journal of Medical Genetics Part A</i> , 1993, 45, 696-697.	2.4	1
661	Diagnosis of Huntington disease: A model for the stages of psychological response based on experience of a predictive testing program. <i>American Journal of Medical Genetics Part A</i> , 1993, 47, 368-374.	2.4	34
662	South African founder mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia in the Dutch population. <i>Human Genetics</i> , 1993, 92, 567-570.	1.8	25
663	The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. <i>Nature Genetics</i> , 1993, 4, 398-403.	9.4	1,002
664	Molecular analysis of new mutations for Huntington's disease: intermediate alleles and sex of origin effects. <i>Nature Genetics</i> , 1993, 5, 174-179.	9.4	248
665	Identification of an Alu retrotransposition event in close proximity to a strong candidate gene for Huntington's disease. <i>Nature</i> , 1993, 362, 370-373.	13.7	50
666	Development of a program for identification of patients with familial hypercholesterolemia in British Columbia: A model for prevention of coronary disease. <i>American Journal of Cardiology</i> , 1993, 72, D25-D29.	0.7	6

#	ARTICLE	IF	CITATIONS
667	Acidic and basic fibroblast growth factor-like immunoreactivity in the striatum and midbrain in Huntington's disease. <i>Brain Research</i> , 1993, 610, 1-7.	1.1	33
668	Mapping of the Human NMDA Receptor Subunit (NMDAR1) and the Proposed NMDA Receptor Glutamate-Binding Subunit (NMDARA1) to Chromosomes 9q34.3 and Chromosome 8, Respectively. <i>Genomics</i> , 1993, 17, 237-239.	1.3	19
669	Molecular analysis of juvenile Huntington disease: the major influence on (CAG) _n repeat length is the sex of the affected parent. <i>Human Molecular Genetics</i> , 1993, 2, 1535-1540.	1.4	189
670	A PCR method for accurate assessment of trinucleotide repeat expansion in Huntington disease. <i>Human Molecular Genetics</i> , 1993, 2, 635-636.	1.4	74
671	Prevention of raised low-density lipoprotein cholesterol in a patient with familial hypercholesterolaemia and lipoprotein lipase deficiency. <i>Lancet, The</i> , 1993, 341, 1119-1121.	6.3	34
672	Monoamines and their metabolites in Huntington's disease brain: Evidence for decreased catechol-O-methyltransferase activity. <i>Biological Psychiatry</i> , 1993, 33, 551-553.	0.7	4
673	(CA) _n -dinucleotide repeat at the PDEB locus in 4p16.3. <i>Human Molecular Genetics</i> , 1993, 2, 827-827.	1.4	7
674	A transcription map of the region containing the Huntington disease gene. <i>Human Molecular Genetics</i> , 1993, 2, 901-907.	1.4	42
675	An Alu element retroposition in two families with Huntington disease defines a new active Alu subfamily. <i>Nucleic Acids Research</i> , 1993, 21, 3379-3383.	6.5	49
676	Five year study of prenatal testing for Huntington's disease: demand, attitudes, and psychological assessment.. <i>Journal of Medical Genetics</i> , 1993, 30, 549-556.	1.5	96
677	George Huntington: the man behind the eponym.. <i>Journal of Medical Genetics</i> , 1993, 30, 406-409.	1.5	12
678	Differential 3' polyadenylation of the Huntington disease gene results in two mRNA species with variable tissue expression. <i>Human Molecular Genetics</i> , 1993, 2, 1541-1545.	1.4	94
679	Molecular analysis of late onset Huntington's disease.. <i>Journal of Medical Genetics</i> , 1993, 30, 991-995.	1.5	57
680	A 4 basepair deletion in exon 4 of the human lipoprotein lipase gene results in type I hyperlipoproteinemia. <i>Human Molecular Genetics</i> , 1993, 2, 1049-1050.	1.4	4
681	Familial predisposition to recurrent mutations causing Huntington's disease: genetic risk to sibs of sporadic cases.. <i>Journal of Medical Genetics</i> , 1993, 30, 987-990.	1.5	34
682	Phenotypic variation of mutations in the human lipoprotein-lipase gene. <i>Biochemical Society Transactions</i> , 1993, 21, 506-509.	1.6	17
683	The Psychological Consequences of Predictive Testing for Huntington's Disease. <i>Obstetrical and Gynecological Survey</i> , 1993, 48, 248-250.	0.2	7
684	SORFIND: A COMPUTER PROGRAM THAT PREDICTS EXONS IN VERTEBRATE GENOMIC DNA. , 1993, , .		1

#	ARTICLE	IF	CITATIONS
685	On planting alfalfa and growing orchids: the cloning of the gene causing Huntington disease. <i>Clinical Genetics</i> , 1993, 43, 217-222.	1.0	2
686	Familial defective apolipoprotein B-100 is clinically indistinguishable from familial hypercholesterolemia. <i>Archives of Internal Medicine</i> , 1993, 153, 2349-2356.	4.3	18
687	Attitudes toward direct predictive testing for the Huntington disease gene. Relevance for other adult-onset disorders. The Canadian Collaborative Group on Predictive Testing for Huntington Disease. <i>JAMA - Journal of the American Medical Association</i> , 1993, 270, 2321-2325.	3.8	44
688	Recurrent pancreatitis and chylomicronemia in an extended Dutch kindred is caused by a Gly154→Ser substitution in lipoprotein lipase. <i>Journal of Lipid Research</i> , 1993, 34, 2109-2119.	2.0	26
689	Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase (LCAT) deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease. <i>Journal of Clinical Investigation</i> , 1993, 91, 677-683.	3.9	80
690	Gene-environment interaction in the conversion of a mild-to-severe phenotype in a patient homozygous for a Ser172→Cys mutation in the lipoprotein lipase gene. <i>Journal of Clinical Investigation</i> , 1993, 91, 1953-1958.	3.9	59
691	The prediction of exons through an analysis of spliceable open reading frames. <i>Nucleic Acids Research</i> , 1992, 20, 3453-3462.	6.5	77
692	The lipoprotein lipase Gly188→Glu mutation in South Africans of Indian descent: evidence suggesting common origins and an increased frequency. <i>Journal of Medical Genetics</i> , 1992, 29, 119-122.	1.5	13
693	(CA) _n -dinucleotide repeat polymorphism at the locus for the alpha _{2C} adrenergic receptor (ADRA _{2C}) on 4p16. <i>Human Molecular Genetics</i> , 1992, 1, 452-452.	1.4	9
694	Predictive testing for Huntington disease. <i>Journal of Medical Ethics</i> , 1992, 18, 47-48.	1.0	3
695	The Psychological Consequences of Predictive Testing for Huntington's Disease. <i>New England Journal of Medicine</i> , 1992, 327, 1401-1405.	13.9	447
696	New Insights Into the Clinical Features, Pathogenesis and Molecular Genetics of Huntington Disease. <i>Brain Pathology</i> , 1992, 2, 321-335.	2.1	51
697	A missense mutation (Asp250→Asn) in exon 6 of the human lipoprotein lipase gene causes chylomicronemia in patients of different ancestries. <i>Genomics</i> , 1992, 13, 649-653.	1.3	43
698	Nonrandom association between huntington disease and two loci separated by about 3 Mb on 4p16.3. <i>Genomics</i> , 1992, 13, 301-311.	1.3	31
699	The human ρ -subunit of rod photoreceptor cGMP phosphodiesterase: Complete retinal cDNA sequence and evidence for expression in brain. <i>Genomics</i> , 1992, 13, 698-704.	1.3	35
700	Mapping of the epitope on lipoprotein lipase recognized by a monoclonal antibody (5D2) which inhibits lipase activity. <i>Lipids and Lipid Metabolism</i> , 1992, 1128, 113-115.	2.6	49
701	Geographic distribution and genealogy of mutation 207 of the lipoprotein lipase gene in the French Canadian population of Quebec. <i>Human Genetics</i> , 1992, 89, 671-675.	1.8	35
702	Auxiliary-directed dioxygenation: stereoselective synthesis of a diene hydroperoxide. <i>Tetrahedron Letters</i> , 1992, 33, 443-446.	0.7	17

#	ARTICLE	IF	CITATIONS
703	Exclusion of DNA changes in the β -subunit of the cGMP phosphodiesterase gene as the cause for Huntington's disease. <i>Nature Genetics</i> , 1992, 1, 104-108.	9.4	12
704	Delineation of a 50 kilobase DNA segment containing the recombination site in a sporadic case of Huntington's disease. <i>Nature Genetics</i> , 1992, 2, 216-222.	9.4	7
705	A missense mutation Pro157Arg in lipoprotein lipase (LPLNijmegen) resulting in loss of catalytic activity. <i>FEBS Journal</i> , 1992, 208, 267-272.	0.2	18
706	Linkage studies and mutation analysis of the PDEB gene in 23 families with leber congenital amaurosis. <i>Human Mutation</i> , 1992, 1, 478-485.	1.1	6
707	Predictive testing for Huntington disease in Canada: The experience of those receiving an increased risk. <i>American Journal of Medical Genetics Part A</i> , 1992, 42, 499-507.	2.4	163
708	Predictive testing for Huntington disease in Canada: Adverse effects and unexpected results in those receiving a decreased risk. <i>American Journal of Medical Genetics Part A</i> , 1992, 42, 508-515.	2.4	225
709	Prevalence, geographical distribution and genealogical investigations of mutation 188 of lipoprotein lipase gene in the French Canadian population of Qu \acute{e} bec. <i>Clinical Genetics</i> , 1992, 41, 206-210.	1.0	26
710	Cortical glucose metabolism in Huntington's disease. <i>Neurology</i> , 1992, 42, 223-223.	1.5	87
711	Identification of multiple CpG islands and associated conserved sequences in a candidate region for the Huntington disease gene. <i>Genomics</i> , 1991, 11, 1113-1124.	1.3	21
712	A low-copy repeat located in subtelomeric regions of 14 different human chromosomal termini. <i>Cytogenetic and Genome Research</i> , 1991, 57, 179-183.	0.6	12
713	Genetic variants affecting human lipoprotein and hepatic lipases. <i>Current Opinion in Lipidology</i> , 1991, 2, 104-109.	1.2	54
714	The FDG/PET Methodology for Early Detection of Disease Onset: A Statistical Model. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1991, 11, A96-A102.	2.4	37
715	Predictive testing for Huntington disease: Are we ready for widespread community implementation?. <i>American Journal of Medical Genetics Part A</i> , 1991, 40, 515-517.	2.4	17
716	Intrachromosomal location of the telomeric repeat (TTAGGG) $_n$. <i>Mammalian Genome</i> , 1991, 1, 211-216.	1.0	28
717	Genomic organization and complete sequence of the human gene encoding the β -subunit of the cGMP phosphodiesterase and its localisation to 4p16.3. <i>Nucleic Acids Research</i> , 1991, 19, 6263-6268.	6.5	57
718	A polymorphic DNA marker at the D8S131 locus. <i>Nucleic Acids Research</i> , 1991, 19, 1725-1725.	6.5	0
719	A Mutation in the Human Lipoprotein Lipase Gene as the Most Common Cause of Familial Chylomicronemia in French Canadians. <i>New England Journal of Medicine</i> , 1991, 324, 1761-1766.	13.9	100
720	Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia.. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1991, 11, 290-297.	3.8	160

#	ARTICLE	IF	CITATIONS
721	Amino acid substitution (Ile194→Thr) in exon 5 of the lipoprotein lipase gene causes lipoprotein lipase deficiency in three unrelated probands. Support for a multicentric origin.. Journal of Clinical Investigation, 1991, 87, 2005-2011.	3.9	69
722	Regional Cerebral Glucose Metabolism in Turner Syndrome. Canadian Journal of Neurological Sciences, 1990, 17, 140-144.	0.3	82
723	DNA testing for Huntington disease results in a modification of risk and not diagnosis of disease. European Journal of Pediatrics, 1990, 149, 513-513.	1.3	1
724	Characterization and organization of DNA sequences adjacent to the human telomere associated repeat (TTAGGG) _n . Nucleic Acids Research, 1990, 18, 3353-3361.	6.5	57
725	A missense mutation at codon 188 of the human lipoprotein lipase gene is a frequent cause of lipoprotein lipase deficiency in persons of different ancestries.. Journal of Clinical Investigation, 1990, 86, 728-734.	3.9	157
726	Different options for prenatal testing for Huntington's disease using DNA probes.. Journal of Medical Genetics, 1989, 26, 353-357.	1.5	19
727	Non-random association between alleles detected at D4S95 and D4S98 and the Huntington's disease gene.. Journal of Medical Genetics, 1989, 26, 676-681.	1.5	75
728	Insurance and the Presymptomatic Diagnosis of Delayed-Onset Disease. JAMA - Journal of the American Medical Association, 1989, 262, 2384.	3.8	1
729	Predictive testing for Huntington disease: I. Description of a pilot project in British Columbia. American Journal of Medical Genetics Part A, 1989, 32, 211-216.	2.4	86
730	Predictive testing for Huntington disease: II. Demographic characteristics, life-style patterns, attitudes, and psychosocial assessments of the first fifty-one test candidates. American Journal of Medical Genetics Part A, 1989, 32, 217-224.	2.4	141
731	Epiphyseal dysplasia, microcephaly, nystagmus, and retinitis pigmentosa. American Journal of Medical Genetics Part A, 1989, 33, 341-345.	2.4	14
732	Huntington disease: No evidence for locus heterogeneity. Genomics, 1989, 5, 304-308.	1.3	56
733	Silent periods, long-latency reflexes and cortical MEPs in Huntington's disease and at-risk relatives. Electroencephalography and Clinical Neurophysiology - Evoked Potentials, 1989, 74, 444-449.	2.0	48
734	A major insertion accounts for a significant proportion of mutations underlying human lipoprotein lipase deficiency.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 948-952.	3.3	110
735	Perinatal and first year follow-up of patients with Prader-Willi syndrome: normal size of hands and feet. Clinical Genetics, 1989, 35, 161-166.	1.0	16
736	Sequence and expression of Tangier apoA-I gene. FEBS Journal, 1988, 173, 465-471.	0.2	30
737	A highly polymorphic locus very tightly linked to the Huntington's disease gene. Nature, 1988, 332, 734-736.	13.7	159
738	Comparison of gemfibrozil and clofibrate on serum lipids in familial combined hyperlipidemia. Atherosclerosis, 1988, 73, 233-240.	0.4	11

#	ARTICLE	IF	CITATIONS
739	Prenatal diagnosis of asplenia/polysplenia syndrome. American Journal of Obstetrics and Gynecology, 1988, 158, 1085-1087.	0.7	28
740	Presymptomatic Neuropsychological Impairment in Huntington's Disease. Archives of Neurology, 1988, 45, 769-773.	4.9	89
741	A polymorphic DNA probe located to human chromosome 4p16 (D4S62). Nucleic Acids Research, 1987, 15, 3938-3938.	6.5	5
742	Apolipoprotein B gene variants are involved in the determination of serum cholesterol levels: a study in normo- and hyperlipidaemic individuals. Atherosclerosis, 1987, 67, 81-89.	0.4	165
743	Insufficient evidence to invoke defects in or around the A-I gene as the cause for familial hypoalphalipoproteinemia. Atherosclerosis, 1987, 67, 271-272.	0.4	0
744	A somatic cell hybrid panel for localizing DNA segments near the Huntington's disease gene. Genomics, 1987, 1, 29-34.	1.3	71
745	Cerebral Glucose and Dopa Metabolism in Movement Disorders. Canadian Journal of Neurological Sciences, 1987, 14, 448-451.	0.3	14
746	Preclinical testing in Huntington disease. American Journal of Medical Genetics Part A, 1987, 27, 733-734.	2.4	16
747	Ethical issues in preclinical testing in Huntington disease: Response to Margery Shaw's invited editorial comment. American Journal of Medical Genetics Part A, 1987, 28, 761-763.	2.4	4
748	Controlling for Cerebral Atrophy in Positron Emission Tomography Data. Journal of Cerebral Blood Flow and Metabolism, 1987, 7, 510-512.	2.4	11
749	Hypoalphalipoproteinemia Resembling Fish Eye Disease. Acta Medica Scandinavica, 1987, 221, 291-298.	0.0	25
750	Arrested Epidermal Morphogenesis in Three Newborn Infants With a Fatal Genetic Disorder (Restrictive Dermopathy).. Journal of Investigative Dermatology, 1987, 88, 330-339.	0.3	52
751	Regression Model for Predicting Dissociations of Regional Cerebral Glucose Metabolism in Individuals at Risk for Huntington's Disease. Journal of Cerebral Blood Flow and Metabolism, 1986, 6, 756-762.	2.4	19
752	Restrictive dermatopathy: A newly recognized autosomal recessive skin dysplasia. American Journal of Medical Genetics Part A, 1986, 24, 631-648.	2.4	96
753	Cerebral metabolism of glucose in benign hereditary chorea. Movement Disorders, 1986, 1, 33-44.	2.2	40
754	Primary Lipoprotein Lipase Deficiency. , 1986, 201, 227-239.		25
755	Positron emission tomography in the early diagnosis of Huntington's disease. Neurology, 1986, 36, 888-888.	1.5	171
756	Deletion of Huntington's disease-linked G8 (D4S10) locus in Wolfâ€™s Hirschhorn syndrome. Nature, 1985, 318, 75-78.	13.7	114

#	ARTICLE	IF	CITATIONS
757	Urinary proteins in a patient with Tangier disease. <i>Clinical Biochemistry</i> , 1985, 18, 98-101.	0.8	3
758	Bilateral renal agenesis in twins. <i>American Journal of Medical Genetics Part A</i> , 1985, 21, 147-152.	2.4	5
759	Down's syndrome and Alzheimer's disease. <i>Annals of Neurology</i> , 1984, 16, 263-263.	2.8	1
760	Reflections on the history of Huntington's chorea. <i>Trends in Neurosciences</i> , 1983, 6, 122-124.	4.2	9
761	The high frequency of juvenile Huntington's chorea in South Africa. <i>Journal of Medical Genetics</i> , 1982, 19, 94-97.	1.5	21
762	Genetic aspects of Huntington's chorea: Results of a national survey. <i>American Journal of Medical Genetics Part A</i> , 1982, 11, 135-141.	2.4	17
763	Huntington's Chorea. , 1981, , .		246
764	Living with Huntington's Chorea: The Social Perspective. , 1981, , 123-135.		3